Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
þ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2017
2021
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 001-36569
LANTHEUS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)


Delaware35-2318913
(State or other jurisdiction of incorporation or organization)(IRS Employer Identification No.)
Delaware35-2318913
(State or other jurisdiction of
incorporation or organization)
(IRS Employer
Identification No.)
331 Treble Cove Road North Billerica, MA01862
North Billerica,MA
(Address of principal executive offices)(Zip Code)
(978)
671-8001

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per shareLNTHThe Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  þ☑    No  ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  þ☑    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐☑Accelerated filer☐
Non-accelerated filer
þ  (Do not check if a smaller reporting company)
☐		Smaller reporting company☐
Emerging Growth Companyþ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   þ☐

Table of Contents
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act)    Yes  ☐    No  þ☑
The registrant had 37,505,99667,690,586 shares of common stock, $0.01 par value, outstanding as of October 31, 2017.
28, 2021.

LANTHEUS HOLDINGS, INC.
TABLE OF CONTENTS

Table of Contents
LANTHEUS HOLDINGS, INC.
TABLE OF CONTENTS
Page

1

2
3
4
46
58
1525
2938
2938
3039
40
Risk Factors
30
Item 2.
3245
3245
3245
45
3246
Exhibits47
33
SIGNATURES
34


Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Lantheus Holdings, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands, except par value)
September 30,
2017		 December 31,
2016		September 30,
2021		December 31,
2020
Assets   Assets
Current assets   Current assets
Cash and cash equivalents$68,077
 $51,178
Cash and cash equivalents$91,475 $79,612 
Accounts receivable, net41,713
 36,818
Accounts receivable, net64,054 54,002 
Inventory23,032
 17,640
Inventory33,949 35,744 
Other current assets3,789
 5,183
Other current assets12,043 9,625 
Assets held for saleAssets held for sale— 5,242 
Total current assets136,611
 110,819
Total current assets201,521 184,225 
Property, plant & equipment, net94,516
 94,187
Property, plant and equipment, netProperty, plant and equipment, net116,441 120,171 
Intangibles, net12,645
 15,118
Intangibles, net356,883 376,012 
Goodwill15,714
 15,714
Goodwill61,189 58,632 
Deferred tax assets, netDeferred tax assets, net66,493 70,147 
Other long-term assets21,535
 20,060
Other long-term assets45,289 60,634 
Total assets$281,021
 $255,898
Total assets$847,816 $869,821 
Liabilities and Stockholders’ Deficit   
Liabilities and stockholders’ equityLiabilities and stockholders’ equity
Current liabilities   Current liabilities
Current portion of long-term debt$2,750
 $3,650
Revolving line of credit—
 —
Current portion of long-term debt and other borrowingsCurrent portion of long-term debt and other borrowings$10,356 $20,701 
Accounts payable18,756
 18,940
Accounts payable20,508 16,284 
Accrued expenses and other liabilities24,581
 21,249
Accrued expenses and other liabilities46,039 41,726 
Liabilities held for saleLiabilities held for sale— 1,793 
Total current liabilities46,087
 43,839
Total current liabilities76,903 80,504 
Asset retirement obligations10,151
 9,370
Asset retirement obligations15,185 14,020 
Long-term debt, net265,523
 274,460
Long-term debt, net and other borrowingsLong-term debt, net and other borrowings166,741 197,699 
Other long-term liabilities37,176
 34,745
Other long-term liabilities89,643 63,393 
Total liabilities358,937
 362,414
Total liabilities348,472 355,616 
Commitments and contingencies (See Note 12)
 
Stockholders’ deficit   
Commitments and contingencies (See Note 19)Commitments and contingencies (See Note 19)00
Stockholders’ equityStockholders’ equity
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)—
 —
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)— — 
Common stock ($0.01 par value, 250,000 shares authorized; 37,498 and 36,756 shares issued and outstanding, respectively)375
 367
Common stock ($0.01 par value, 250,000 shares authorized; 67,659 and 66,875 shares issued and outstanding, respectively)Common stock ($0.01 par value, 250,000 shares authorized; 67,659 and 66,875 shares issued and outstanding, respectively)677 669 
Additional paid-in capital228,934
 226,462
Additional paid-in capital680,819 665,530 
Accumulated deficit(306,139) (332,398)Accumulated deficit(181,010)(149,946)
Accumulated other comprehensive loss(1,086) (947)Accumulated other comprehensive loss(1,142)(2,048)
Total stockholders’ deficit(77,916) (106,516)
Total liabilities and stockholders’ deficit$281,021
 $255,898
Total stockholders’ equityTotal stockholders’ equity499,344 514,205 
Total liabilities and stockholders’ equityTotal liabilities and stockholders’ equity$847,816 $869,821 
The accompanying notes are an integral part of these condensed consolidated financial statements.

1
Table of Contents
Lantheus Holdings, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share data)
Three Months Ended
September 30,		 Nine Months Ended
September 30,		Three Months Ended
September 30,		Nine Months Ended
September 30,
2017 2016 2017 20162021202020212020
Revenues$79,941
 $73,063
 $250,137
 $227,503
Revenues$102,073 $88,544 $295,646 $245,258 
Cost of goods sold41,414
 39,382
 125,901
 124,370
Cost of goods sold59,404 52,284 165,859 145,148 
Gross profit38,527
 33,681
 124,236
 103,133
Gross profit42,669 36,260 129,787 100,110 
Operating expenses       Operating expenses
Sales and marketing10,075
 8,706
 31,892
 27,856
Sales and marketing17,195 11,609 48,999 28,044 
General and administrative12,076
 10,091
 35,549
 28,842
General and administrative28,550 18,217 87,865 55,586 
Research and development3,554
 2,849
 14,149
 8,493
Research and development11,252 11,684 33,673 20,150 
Total operating expenses25,705
 21,646
 81,590
 65,191
Total operating expenses56,997 41,510 170,537 103,780 
Gain on sales of assets—
 (560) —
 (6,505)
Operating income12,822
 12,595
 42,646
 44,447
Gain on sale of assetsGain on sale of assets— — 15,263 — 
Operating lossOperating loss(14,328)(5,250)(25,487)(3,670)
Interest expense4,442
 6,792
 14,147
 20,799
Interest expense1,569 2,808 6,224 6,668 
Debt retirement costs—
 1,415
 —
 1,415
Loss on extinguishment of debt—
 —
 2,161
 —
Other (income) expense(908) 148
 (2,037) (317)
Income before income taxes9,288
 4,240
 28,375
 22,550
Provision for income taxes762
 20
 2,116
 657
Net income$8,526
 $4,220
 $26,259
 $21,893
Net income per common share outstanding:       
Gain on extinguishment of debtGain on extinguishment of debt— — (889)— 
Other loss (income)Other loss (income)3,940 (596)3,209 (1,702)
Loss before income taxes Loss before income taxes(19,837)(7,462)(34,031)(8,636)
Income tax (benefit) expenseIncome tax (benefit) expense(6,422)(1,076)(2,967)1,425 
Net lossNet loss$(13,415)$(6,386)$(31,064)$(10,061)
Net loss per common share:Net loss per common share:
Basic$0.23
 $0.14
 $0.71
 $0.71
Basic$(0.20)$(0.10)$(0.46)$(0.20)
Diluted$0.22
 $0.13
 $0.67
 $0.71
Diluted$(0.20)$(0.10)$(0.46)$(0.20)
Weighted-average common shares outstanding:       Weighted-average common shares outstanding:
Basic37,393
 31,221
 37,174
 30,658
Basic67,623 66,820 67,409 49,858 
Diluted39,121
 32,402
 38,971
 31,049
Diluted67,623 66,820 67,409 49,858 
The accompanying notes are an integral part of these condensed consolidated financial statements.

2
Table of Contents
Lantheus Holdings, Inc.
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
(in thousands)
Three Months Ended
September 30,		Nine Months Ended
September 30,
Three Months Ended
September 30,		 Nine Months Ended
September 30,		2021202020212020
Net lossNet loss$(13,415)$(6,386)$(31,064)$(10,061)
Other comprehensive (loss) income:Other comprehensive (loss) income:
2017 2016 2017 2016
Net income$8,526
 $4,220
 $26,259
 $21,893
Other comprehensive (loss) income:       
Reclassification adjustment for gains on sales of assets included in net income—
 435
 —
 435
Foreign currency translation(115) 234
 (139) 490
Foreign currency translation(240)185 55 (9)
Unrealized gain (loss) on cash flow hedges, net of taxUnrealized gain (loss) on cash flow hedges, net of tax98 (89)851 (1,541)
Total other comprehensive (loss) income(115) 669
 (139) 925
Total other comprehensive (loss) income(142)96 906 (1,550)
Total comprehensive income$8,411
 $4,889
 $26,120
 $22,818
Comprehensive lossComprehensive loss$(13,557)$(6,290)$(30,158)$(11,611)
The accompanying notes are an integral part of these condensed consolidated financial statements.

3
Table of Contents
Lantheus Holdings, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)
(in thousands)

Nine Months Ended September 30, 2021
Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated
Other
Comprehensive
Loss		Total
Stockholders’
Equity
SharesAmount
Balance, January 1, 202166,875 $669 $665,530 $(149,946)$(2,048)$514,205 
Net income— — — 9,008 — 9,008 
Other comprehensive income— — — — 808 808 
Stock option exercises and employee stock plan purchases155 1 2,379 — — 2,380 
Vesting of restricted stock awards and units489 5 (5)— — — 
Shares withheld to cover taxes(85)(1)(1,598)— — (1,599)
Stock-based compensation— — 3,317 — — 3,317 
Balance, March 31, 202167,434 $674 $669,623 $(140,938)$(1,240)$528,119 
Net loss— — — (26,657)— (26,657)
Other comprehensive income— — — — 240 240 
Stock option exercises and employee stock plan purchases116 1 2,042 — — 2,043 
Vesting of restricted stock awards and units51 1 (1)— — — 
Shares withheld to cover taxes(9)— (193)— — (193)
Stock-based compensation— — 4,588 — — 4,588 
Balance, June 30, 202167,592 $676 $676,059 $(167,595)$(1,000)$508,140 
Net loss— — — (13,415)— (13,415)
Other comprehensive loss— — — — (142)(142)
Stock option exercises and employee stock plan purchases48 1 960 — — 961 
Vesting of restricted stock awards and units23 — — — — — 
Shares withheld to cover taxes(4)— (67)— — (67)
Stock-based compensation— — 3,867 — — 3,867 
Balance, September 30, 202167,659 $677 $680,819 $(181,010)$(1,142)$499,344 


4
Table of Contents
Nine Months Ended September 30, 2020
Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated
Other
Comprehensive
Loss		Total
Stockholders’
Equity
SharesAmount
Balance, January 1, 202039,251 $393 $251,641 $(136,473)$(960)$114,601 
Net income— — — 3,337 — 3,337 
Other comprehensive loss— — — — (1,434)(1,434)
Stock option exercises and employee stock plan purchases33 — 366 — — 366 
Vesting of restricted stock awards and units563 6 (6)— — — 
Shares withheld to cover taxes(97)(1)(1,546)— — (1,547)
Stock-based compensation— — 3,075 — — 3,075 
Balance, March 31, 202039,750 $398 $253,530 $(133,136)$(2,394)$118,398 
Net loss— — — (7,012)— (7,012)
Other comprehensive loss— — — — (212)(212)
Stock option exercises and employee stock plan purchases7 — 50 — — 50 
Vesting of restricted stock awards and units242 2 (2)— — — 
Shares withheld to cover taxes(36)(1)(484)— — (485)
Issuance of common stock, net of $3,776 issuance costs26,845 269 394,065 — — 394,334 
Fair value of replacement options related to pre-acquisition services— — 7,125 — — 7,125 
Stock-based compensation— — 3,385 — — 3,385 
Balance, June 30, 202066,808 $668 $657,669 $(140,148)$(2,606)$515,583 
Net loss— — — (6,386)— (6,386)
Other comprehensive income— — — — 96 96 
Stock option exercises and employee stock plan purchases32 — 344 — — 344 
Vesting of restricted stock awards and units13 1 (1)— — — 
Shares withheld to cover taxes(3)(1)(49)— — (50)
Stock-based compensation— — 3,992 — — 3,992 
Balance, September 30, 202066,850 $668 $661,955 $(146,534)$(2,510)$513,579 


The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Table of Contents
Lantheus Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Nine Months Ended
September 30,
20212020
Operating activities
Net loss$(31,064)$(10,061)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation, amortization and accretion30,088 16,295 
Impairment of long-lived assets9,540 7,275 
Amortization of debt related costs430 199 
Changes in fair value of contingent assets and liabilities28,500 800 
Gain on extinguishment of debt(889)— 
Provision for excess and obsolete inventory2,317 1,870 
Stock-based compensation11,772 10,452 
Gain on sale of assets(15,263)— 
Deferred taxes1,028 (781)
Long-term income tax receivable3,092 (1,664)
Long-term income tax payable and other long-term liabilities(3,617)2,114 
Other1,724 1,034 
(Decreases) increases in cash from operating assets and liabilities:
Accounts receivable(7,721)(703)
Inventory(625)(9,593)
Other current assets1,998 1,563 
Accounts payable4,776 3,762 
Accrued expenses and other liabilities3,941 (6,735)
Net cash provided by operating activities40,027 15,827 
Investing activities
Capital expenditures(7,596)(8,689)
Proceeds from sale of assets, net15,823 — 
Lending on bridge loan— (10,000)
Cash acquired in acquisition of business— 17,562 
Net cash provided by (used in) investing activities8,227 (1,127)
Financing activities
Payments on long-term debt and other borrowings(40,757)(11,166)
Equity issuance costs— (3,777)
Deferred financing costs— (1,223)
Proceeds from stock option exercises4,616 77 
Proceeds from issuance of common stock768 683 
Payments for minimum statutory tax withholding related to net share settlement of equity awards(1,859)(2,082)
Net cash used in financing activities(37,232)(17,488)
Effect of foreign exchange rates on cash, cash equivalents and restricted cash(99)4 
Net increase (decrease) in cash, cash equivalents and restricted cash10,923 (2,784)
Cash, cash equivalents and restricted cash, beginning of period82,694 92,919 
Cash, cash equivalents and restricted cash, end of period$93,617 $90,135 

6
Table of Contents
 Nine Months Ended
September 30,
 2017 2016
Operating activities   
Net income$26,259
 $21,893
Adjustments to reconcile net income to net cash flows from operating activities:   
Depreciation, amortization and accretion15,019
 12,664
Amortization of debt related costs1,031
 1,235
Provision for excess and obsolete inventory1,002
 982
Stock-based compensation3,764
 1,869
Gain on sales of assets—
 (6,505)
Loss on extinguishment of debt and debt retirement costs2,161
 1,415
Other1,404
 (254)
Increases (decreases) in cash from operating assets and liabilities:   
Accounts receivable(4,609) 1,071
Inventory(6,361) (1,658)
Other current assets54
 (1,032)
Accounts payable(270) 2,684
Accrued expenses and other liabilities2,237
 2,497
Net cash provided by operating activities41,691
 36,861
Investing activities   
Proceeds from sales of assets1,234
 10,541
Capital expenditures(11,589) (4,976)
Other—
 74
Net cash (used in) provided by investing activities(10,355) 5,639
Financing activities   
Payments on long-term debt(285,979) (57,790)
Proceeds from issuance of long-term debt274,313
 —
Proceeds from issuance of common stock187
 41,600
Payments for public offering costs—
 (1,266)
Proceeds from stock option exercises1,210
 61
Payments for minimum statutory tax withholding related to net share settlement of equity awards(2,681) (552)
Deferred financing costs(1,576) (11)
Other(74) —
Net cash used in financing activities(14,600) (17,958)
Effect of foreign exchange rates on cash and cash equivalents163
 57
Net increase in cash and cash equivalents16,899
 24,599
Cash and cash equivalents, beginning of period51,178
 28,596
Cash and cash equivalents, end of period$68,077
 $53,195
Lantheus Holdings, Inc.
Condensed Consolidated Statements of Cash Flows (Continued)
(Unaudited)
(in thousands)
Nine Months Ended
September 30,
20212020
Reconciliation to amounts within the condensed consolidated balance sheets
  Cash and cash equivalents$91,475 $87,994 
  Restricted cash included in other long-term assets2,142 2,141 
      Cash, cash equivalents and restricted cash at end of period$93,617 $90,135 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7
Table of Contents
Lantheus Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note Regarding Company References and Trademarks
Unless the context otherwise requires, references to the “Company” and “Lantheus” refer to Lantheus Holdings, Inc. and its direct and indirect wholly-owned subsidiaries, references to “Holdings” refer to Lantheus Holdings, Inc. and not to any of its subsidiaries, and references to “LMI” refer to Lantheus Medical Imaging, Inc., the direct subsidiary of Holdings.Holdings and references to “Progenics” refer to Progenics Pharmaceuticals, Inc., a wholly-owned subsidiary of LMI. Solely for convenience, the Company refers to trademarks, service marks and trade names without the ™, TM, SM and ® symbols. Those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks, service marks and trade names.
1. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements include the accounts of Lantheus Holdings Inc. and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three and nine months ended September 30, 20172021 are not necessarily indicative of the results that may be expected for the year ended December 31, 20172021 or any future period.
In the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, which resulted in a change in operating segments. Please refer to Note 20, “Segment Information”, for further details.
The condensed consolidated balance sheet at December 31, 20162020 has been derived from the audited consolidated financial statements at that date but does not include all of the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 20162020 filed with the Securities Exchange Commission (“SEC”) on February 23, 2017. 25, 2021.
Progenics Acquisition
On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the previously announced acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”).
In accordance with the Merger Agreement, at the effective time of the Progenics Acquisition (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) 1 contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen (“PSMA”) targeted imaging agent designed to visualize prostate cancer. This agent was approved by the U.S. Food and Drug Administration (“FDA”) on May 26, 2021 under the name PYLARIFY (piflufolastat F 18), and the commercial launch of this agent has begun. Each CVR will entitle its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% of the total consideration the Company pays in the Progenics Acquisition (which the Company estimates could be approximately $100.0 million). No fractional shares of Holdings common stock were issued in the Progenics Acquisition, and Progenics’ former stockholders have received cash in lieu of any fractional shares of Holdings common stock. As a result of the acquisition, Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders.
Please refer to Note 8, “Business Combinations”, for further details on the acquisition.
COVID-19
8
Table of Contents
The Company experienced operational and financial impacts from the COVID-19 pandemic beginning late in the first quarter of 2020 and through the date of this filing, including the impact of stay-at-home mandates and advisories, and a decline in the volume of certain procedures and treatments using the Company’s products. For example, there has been a substantial reduction in pulmonary ventilation studies in which the Company’s product, Xenon, is used. As a result of the COVID-19 pandemic, the Company undertook a thorough analysis of all its discretionary expenses. In the first quarter of 2020, the Company implemented certain cost reduction initiatives. For most of the second quarter of 2020, the Company reduced the Company’s work week from 5 days to 4 days and reduced the pay for employees by varying amounts depending on level of seniority.
During the second quarter of 2020, Progenics also implemented certain cost reduction initiatives and paused new enrollment in the ARROW Phase 2 study of 1095, a PSMA-targeted therapeutic, in metastatic castrate-resistant prostate cancer (“mCRPC”) patients to minimize the risk to subjects and healthcare providers during the pandemic. New enrollment in that study restarted in October 2020. GE Healthcare Limited (“GE Healthcare”), the Company’s development and commercialization partner for flurpiridaz fluorine-18 (“F 18”), also delayed enrollment in the second Phase 3 clinical trial of flurpiridaz F 18 because of the pandemic and resumed enrollment in the third quarter of 2020.
Although some of the restrictions, including stay-at-home mandates, imposed in response to the COVID-19 pandemic have been lifted in much of the United States (the “U.S.”), and there has been a rapid rollout and development of certain vaccines, the resurgence of COVID-19 infections did impact certain aspects of the Company’s business during the third quarter of 2021 and the pandemic could still have a future negative impact on the Company's business, particularly if there are additional resurgences as a result of mutations or other variations to the virus that increase its communicability or its impact on certain populations, geographic regions and the healthcare system, including elective procedures and hospital access. While the impact of COVID-19 on the Company’s results of operations and cash flows has been material, given continued uncertainty about the future trajectory of the pandemic, the Company remains unable to accurately predict the impact of COVID-19 on its overall 2021 operations and financial results or cash flows and whether the on-going impact of COVID-19 could lead to potential future impairments.
2. Summary of Significant Accounting Policies
Reclassifications
Certain immaterial amountsreclassifications in the prior period condensed consolidated statements of cash flows have been reclassified to conform to the current year period financial statement presentation.
Manufacturing Concentrations
Reclassifications include $0.2 million from provision for bad debt to other at September 30, 2020. The Company currently relies on Jubilant HollisterStier (“JHS”) as its sole source manufacturer of DEFINITY, Neurolite, Cardiolitehad a reclassification in presentation related to rebates and evacuation vialsallowances within product revenue. Please refer to Note 3, “Revenue from Contracts with Customers” for TechneLite. The Company has on-going development and technology transfer activities for a next generation DEFINITY product with Samsung BioLogics (“SBL”) located in Songdo, South Korea, approximately 20 miles southwest of Seoul, but can give no assurances as to when those technology transfer activities will be completed and when the Company will begin to receive supply of a next generation DEFINITY product from SBL. In addition, those activities could be adversely affected by on-going political and military tensions on the Korean peninsula.
2. Summary of Significant Accounting Policies
Collaboration and License Agreement with GE Healthcare Limited
On April 25, 2017, the Company announced that it entered into a definitive, exclusive Collaboration and License Agreement (the “License Agreement”) with GE Healthcare Limited (“GE Healthcare”) for the continued Phase III development and worldwide commercialization of flurpiridaz F 18, an investigational positron emission tomography myocardial perfusion imaging agent that may improve the diagnosis of coronary artery disease. Under the License Agreement, GE Healthcare will complete the worldwide development of flurpiridaz F 18, pursue worldwide regulatory approvals and, if successful, lead a worldwide launch and commercialization of the agent, with LMI collaborating on both development and commercialization through a joint steering committee. LMI has an option to co-promote the agent in the U.S. GE Healthcare’s development plan will initially focus on obtaining regulatory approval for flurpiridaz F 18 in the U.S., Japan, Europe and Canada.

Under the terms of the License Agreement, the Company received an up-front payment of $5.0 million. In addition, the Company is eligible to receive, from GE Healthcare, up to $60 million in regulatory and sales-based milestones and tiered double-digit royalties on U.S. sales and mid-single digit royalties on sales outside the U.S. Because the Company concluded there was only one significant deliverable under the License Agreement, consisting of the license of the product which occurred upon the signing of the License Agreement, the Company recognized $5.0 million associated with entering into the license as revenue during the nine months ended September 30, 2017. In addition, because the Company concluded that the regulatory and sales-based milestones are solely dependent on GE Healthcare’s performance and there are no continuing performance obligations from the Company, all development and sales milestones under the License Agreement are considered non-substantive. As of September 30, 2017, the Company has not recognized revenue for those milestones under the License Agreement and will recognize such revenue in the periods in which the milestones are achieved. Similarly, the Company will recognize royalty revenues in the periods of the sale of the related products, provided that the reported sales are reliably measurable, collectability is reasonably assured and the Company has no further performance obligations.details.
Recent Accounting Pronouncements
The following table provides a description of recent accounting pronouncements that may have a material effect on the Company’s condensed consolidated financial statements:
StandardDescriptionDescription
 
Effective Date

for Company

 		Effect on the Condensed Consolidated Financial Statements
Recently Issued Accounting Standards Not Yet Adopted 
ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting
This ASU clarifies when to account for a change to the terms or conditions of a share–based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, vesting conditions or classification of the award (as equity or liability) changes as a result of the change in terms or conditions.
The new guidance will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 for all entities. Early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued or made available for issuance.
January 1, 2018The Company does not expect that the adoption of this standard will have a material impact on the Company’s condensed consolidated financial statements.
ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and related additional amendments ASU 2015-14, ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, ASU 2016-20, ASU 2017-05, ASU 2017-10
This ASU and related amendments affect any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The guidance in this ASU supersedes the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization’s contracts with customers. In August 2015, the Financial Accounting Standards Board issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year.
The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods:
•   A full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or
•   A modified retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).
January 1, 2018
The Company has established an implementation team which includes third-party specialists to assist in the evaluation and implementation of the new standard. The Company has completed its assessment of the impact of the standards on its contract portfolio by reviewing the Company’s current accounting policies and practices and identifying potential differences that would result from applying the requirements of the new standard to its revenue contracts. The Company has categorized its customers into multiple customer types and assessed significant customer arrangements within those customer types. The Company is currently in the process of formalizing its conclusion. At this time, the Company does not anticipate a significant impact to its revenue upon adoption of the new standard. The Company, in part due to the limited anticipated impact, will utilize the modified retrospective approach of adopting the ASU. In addition, during 2017 the Company has begun to identify and implement, if necessary, appropriate changes to its business processes, systems and controls to support recognition and disclosure under the new standard.


StandardDescription
Effective Date
for Company
Effect on the Condensed Consolidated  Financial Statements
Accounting Standards Adopted During the Nine Months Ended September 30, 20172021
ASU 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)”
This ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvementsprovides guidance to Employee Share-Based Payment Accounting
simplify the complexity associated with accounting for convertible instruments and derivatives. For convertible instruments, the number of major separation models required were reduced. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. This ASU 2016-09 simplifies several aspects offurther amends the stock compensation guidance in Topic 718 and other related guidance providingfor the following amendments:
•   Accounting for income taxes upon vesting or exercise of share-based payments and related EPS effects
•   Classification of excess tax benefits on the statement of cash flows
•   Accounting for forfeitures
•   Liability classificationderivatives scope exception for statutory tax withholding requirements
•   Cash flow presentation of employee taxes paid whencontracts in an employer withholds shares for tax-withholding purposes
•   Elimination ofentity’s own equity to reduce form-over-substance-based accounting conclusions. The ASU simplifies the indefinite deferraldiluted net income per share calculation in Topic 718
For public business entities, the amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods.
certain areas as well.		January 1, 20172021The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.
9
Table of Contents
3. Revenue from Contracts with Customers
The following table summarizes revenue by revenue source as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
Major Products/Service Lines (in thousands)2021202020212020
    Product revenue, net(1)

$96,678 $83,661 $277,559 $238,801 
    License and royalty revenues5,395 4,883 18,087 6,457 
Total revenues$102,073 $88,544 $295,646 $245,258 

(1)The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the
same revenue recognition policies and judgments for all its principal products.
The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of PYLARIFY and AZEDRA. Strategic partnerships and other includes partnerships related to other products of the Company, such as RELISTOR.
Revenue by product category on a net basis is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021
2020(1)
2021
2020(1)
   DEFINITY$57,636 $50,359 $173,448 $139,989 
   TechneLite22,680 21,113 69,252 62,560 
   Other precision diagnostics7,563 8,585 21,289 28,782 
Total precision diagnostics87,879 80,057 263,989 231,331 
Radiopharmaceutical oncology8,890 3,323 13,203 7,474 
Strategic partnerships and other5,304 5,164 18,454 6,453 
   Total revenues$102,073 $88,544 $295,646 $245,258 

(1)The Company reclassified rebates and allowances of $5.5 million and $13.8 million within each product category, which included $5.1 million and $12.6 million for DEFINITY, $0.3 million and $0.9 million for TechneLite and $0.1 million and $0.2 million for other precision diagnostics, for the three and nine months ended September 30, 2020, respectively.
The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.
4. Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
•Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
•Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
•Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.
At September 30, 2017 and December 31, 2016, the
10
Table of Contents
The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds.market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 13, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market. Please refer to Note 8, “Business Combinations”, for further details on the acquisition.
The tabletables below presentspresent information about the Company’s assets and liabilitiesliabilities measured at fair value on a recurring basis:
September 30, 2021
(in thousands)Total Fair
Value		Level 1Level 2Level 3
Assets:
   Money market$39,141 $39,141 $— $— 
   Contingent receivable13,800 — — 13,800 
Total assets$52,941 $39,141 $— $13,800 
Liabilities:
   Interest rate swaps$766 $— $766 $— 
   Contingent consideration liabilities46,800 — — 46,800 
Total liabilities$47,566 $— $766 $46,800 
 
Total Fair
Value
 Level 1 Level 2 Level 3
September 30, 2017(in thousands)
Money market funds$6,565
 $6,565
 $—
 $—
 $6,565
 $6,565
 $—
 $—
December 31, 2016       
Money market funds$3,565
 $3,565
 $—
 $—
 $3,565
 $3,565
 $—
 $—
December 31, 2020
(in thousands)Total Fair
Value		Level 1Level 2Level 3
Assets:
   Money market$35,457 $35,457 $— $— 
   Contingent receivable11,300 — — 11,300 
Total assets$46,757 $35,457 $— $11,300 
Liabilities:
   Interest rate swaps$1,908 $— $1,908 $— 
   Contingent consideration liabilities15,800 — — 15,800 
Total liabilities$17,708 $— $1,908 $15,800 


4. Income Taxes
The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full year in addition to discrete events which impact the interim period. The Company’s effective tax rate differs from the U.S. statutory rate principally due to the change in valuation allowance and the rate impact of uncertain tax positions. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective tax rate is determined. The Company’s tax provision was $0.8 million and $20,000 forDuring the three and nine months ended September 30, 20172021, there were no transfers into or out of Level 3.
As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and 2016, respectively,royalty payments due to Progenics from CytoDyn Inc. related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and $2.1a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.
As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Refer to Note 1, “Basis of Presentation” for further details on the CVRs. Additionally, the Company assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and $0.71095 and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the CVRs and the 2013 Acquisition, each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant
11
Table of Contents
estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.
Significant changes in any of the probabilities of success, the probabilities as to the periods in which milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities, including the CVRs, will be consistent with any recurring fair value estimate of such contingent consideration liabilities.
The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at September 30, 2021.

Fair Value atAssumptions
(in thousands)September 30, 2021December 31, 2020Valuation TechniqueUnobservable InputSeptember 30, 2021December 31, 2020
Contingent receivable:
Regulatory milestone$3,300 $3,200 Probability adjusted discounted cash flow modelPeriod of expected milestone achievement20222021
Probability of success90 %90 %
Discount rate18 %24 %
Royalties10,500 8,100 Probability adjusted discounted cash flow model
Probability of success13% - 77%13% - 77%
Discount rate18 %24 %
Total$13,800 $11,300 

Fair Value atAssumptions
(in thousands)September 30, 2021December 31, 2020Valuation TechniqueUnobservable InputSeptember 30, 2021December 31, 2020
Contingent consideration liability:
Net sales targets - PYLARIFY (CVRs)$33,200 $4,200 Monte Carlo simulationPeriod of expected milestone achievement2022 - 20232022 - 2023
Discount rate18 %24 %
1095 commercialization milestone1,900 2,200 Probability adjusted discounted cash flow model
Period of expected milestone achievement20262026
Probability of success40 %45 %
Discount rate0.9 %0.5 %
Net sales targets - AZEDRA and 109511,700 9,400 Monte Carlo simulation
Probability of success40% - 100%40% - 100%
Discount rate17% - 18%23% - 24%
Total$46,800 $15,800 
12
Table of Contents

For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:

Financial AssetsFinancial Liabilities
(in thousands)Nine Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
Fair value, beginning of period$11,300 $— $15,800 $— 
Progenics acquisition— 10,100 — 16,300 
Changes in fair value included in net loss2,500 100 31,000 900 
Fair value, end of period$13,800 $10,200 $46,800 $17,200 
The change in fair value of the contingent financial asset and contingent financial liabilities, including the CVRs, resulted in an expense of $28.5 million for the nine months ended September 30, 20172021 and 2016, respectively.was primarily due to changes in revenue forecasts, changes in market conditions, a decrease in discount rates and the passage of time.
5. Income Taxes
Historically, the Company has calculated its provision for income taxes during its interim reporting periods by applying an estimate of the annual effective tax rate for the full year to “ordinary” income or loss (pretax income or loss excluding unusual or infrequently occurring discrete events). For the three- and nine-month periods ended September 30, 2021, the Company has computed its provision for income taxes under the discrete method, which allows the Company to calculate its tax provision based upon the actual effective tax rate for the year-to-date period. We determined that since small changes in estimated “ordinary” income would result in significant changes in the estimated annual effective tax rate, the historical method would not provide a reliable estimate for the three- and nine-month periods ended September 30, 2021. The Company’s income tax expense is presented below:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021202020212020
Income tax (benefit) expense$(6,422)$(1,076)$(2,967)$1,425 
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence, and weighed the objective evidence and expected impact. EvidenceThe Company assessed the Company considered included its history of net operating losses, which resulted in the Company recordingneed for a full valuation allowance against its domesticcertain state tax credit carryforwards added through the Progenics Acquisition. The Company continues to record other valuation allowances of $1.2 million against the net deferred tax assets beginning in 2011,of its U.K. subsidiary, and in each year thereafter. The Company was profitable on a cumulative basis for$2.0 million against the three-year period ended September 30, 2017, but substantially all of that profitability was achieved during 2016 and the nine months ended September 30, 2017.
The Company continues to evaluate other negative evidence including customer concentration and contractual risk, DEFINITY supplier risk, the risk of Moly supply availability and cost, and certain product development risks, all of which provide for uncertainties around the Company’s future level of profitability. Based on its review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability sufficient to outweigh the objectively verifiable negative evidence, and has recorded a full valuation allowance against its domestic net deferred tax assets at September 30, 2017. The Company will continue to assess the level of the valuation allowance required. If a sufficient weight of positive evidence exists in future periods to support a release of some or all of the valuation allowance recorded against domestic deferred tax assets, such a release would likely have a material impact on the Company’s results of operations in that future period.its Sweden subsidiary.
In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into a tax indemnification agreement with BMS relatedunder which BMS agreed to certainindemnify the Company for any payments made to settle those uncertain tax obligations arising priorpositions with the state taxing authorities. Accordingly, a long-term receivable is recorded to account for the expected value to the acquisitionCompany of future indemnification payments to be paid on behalf of the Company for whichby BMS, net of actual tax benefits received by the Company has the primary legal obligation.Company. The tax indemnification receivable is recognizedrecorded within other long-term assets.
During the third quarter of 2021, the Company entered into a settlement agreement with one state and accordingly reduced the amount of the uncertain tax positions by $5.5 million. The changes insettlement payment to that state and the tax indemnification asset are recognized within other incomepayment from BMS will be made in the condensed consolidated statementfourth quarter of operations. 2021. The Company continues to accrue interest on the outstanding uncertain tax positions.
In accordance with the Company’s accounting policy, the change in the contingent tax liability, andliabilities, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within theincome tax provision. Accordingly, asexpense. As these reserves change (for example, by the state tax settlement noted above), adjustments are included in theincome tax provisionexpense while the offsetting adjustment is included in other income. Assuming that the remaining receivable from BMSBMS continues to be considered recoverable by the Company, there iswill be no net effect on earnings related to these liabilitiesnet income and no net cash outflows.outflows related to these liabilities.
13
Table of Contents
5.In addition to the state tax settlement noted above, for the nine months ended September 30, 2021, the Company released $0.7 million of liabilities for uncertain tax positions, including interest and penalties of $0.5 million. This included a release of liabilities of $0.1 million, including interest and penalties of $0.4 million, due to a change in estimate with respect to the Company’s indemnified uncertain tax positions arising from new information obtained during the year. The remaining release of $0.2 million of liability was due to the lapse of a statute of limitations.
On June 19, 2020, the Company completed the Progenics Acquisition in a transaction that is expected to qualify as a tax-deferred reorganization under Section 368 of the Internal Revenue Code. The transaction resulted in an ownership change of Progenics under Section 382 of the Internal Revenue Code and a limitation on the utilization of Progenics’ precombination tax attributes. All of Progenics’ precombination federal research and Orphan drug credits have been removed from the balance sheet, and the gross carrying value of the tax loss carryforwards reduced to their realizable value on the opening balance sheet, in accordance with the Section 382 limitation. Deferred tax liabilities arising from the purchase accounting basis step-up in identified intangibles were recorded at acquisition, resulting in an initial net overall deferred tax liability for Progenics after the application of acquisition accounting.
The Company finalized the acquisition accounting for income taxes in the first quarter of 2021 resulting in a reduction of deferred tax assets, primarily related to state research credit carryforwards and an increase to goodwill of $2.6 million.
6. Inventory
Inventory consisted of the following:
(in thousands)September 30,
2017
December 31,
2016		(in thousands)September 30,
2021		December 31,
2020
Raw materials$10,699
 $9,658
Raw materials$15,173 $16,000 
Work in process5,571
 3,965
Work in process11,560 11,212 
Finished goods6,762
 4,017
Finished goods7,216 8,532 
Total inventory$23,032
 $17,640
Total inventory$33,949 $35,744 
Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. As of September 30, 2017 and December 31, 2016,2021, the Company had $1.2$3.2 million of inventory classified within other long-term assets,such product costs included in inventories related to DEFINITY that have been manufactured through the Company’s in-house manufacturing capabilities, which represent raw materials not expected to be used by the Company during the next twelve months.is awaiting regulatory approval.

6.7. Property, Plant &and Equipment, Net
Property, plant &and equipment, net, consisted of the following:
(in thousands)September 30,
2017		 December 31,
2016		(in thousands)September 30,
2021		December 31,
2020
Land$14,950
 $14,950
Land$13,450 $13,450 
Buildings74,864
 70,628
Buildings73,285 70,381 
Machinery, equipment and fixtures69,549
 65,407
Machinery, equipment and fixtures82,596 77,854 
Computer software18,463
 18,482
Computer software24,223 23,644 
Construction in progress10,068
 7,224
Construction in progress8,887 11,254 
187,894
 176,691
202,441 196,583 
Less: accumulated depreciation and amortization(93,378) (82,504)Less: accumulated depreciation and amortization(86,000)(76,412)
Total property, plant & equipment, net$94,516
 $94,187
Total property, plant and equipment, netTotal property, plant and equipment, net$116,441 $120,171 
Depreciation and amortization expense related to property, plant &and equipment, net, was $2.7$3.6 million and $3.4 million for the three months ended September 30, 20172021 and 20162020, respectively, and $11.7$9.8 million and $8.1$9.1 million for the nine months ended September 30, 20172021 and 2016,2020, respectively.
14
Table of Contents
7.The Company tests long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. During the three months ended September 30, 2021, the Company reviewed certain facts relating to an asset group that included the right-of-use (“ROU”) asset associated with the lease of office space in the World Trade Center (the “WTC lease”) in New York City and resulted in a change to the asset group due to the negotiation of a sublease. Please refer to Note 16, “Leases” for further details.
During the three months ended March 31, 2020, as a result of a decline in expected future cash flows and the effect of the COVID-19 pandemic related to certain other nuclear legacy manufacturing assets, the Company determined certain impairment triggers had occurred. Accordingly, the Company performed an undiscounted cash flow analysis as of March 31, 2020. Based on the undiscounted cash flow analysis, the Company determined that the manufacturing assets had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair values of the asset group based on their discounted cash flows. The carrying value exceeded the fair value and as a result, the Company recorded a non-cash impairment of $7.3 million for the nine months ended September 30, 2020 in cost of goods sold in the condensed consolidated statements of operations.
8. Business Combinations
On June 19, 2020, the Company completed the Progenics Acquisition. The acquisition combined the commercialization, supply chain and manufacturing expertise of the Company with the currently commercialized products and research and development pipeline of Progenics. Progenics brought to the Company several commercial products and a pipeline of product candidates that further diversify the Company’s commercial and clinical development portfolios.
Under the terms of the Merger Agreement, the Company acquired all the issued and outstanding shares of Progenics common stock for a purchase price of $419.0 million by means of an all-stock transaction, which includes options to purchase Holdings common stock (“Replacement Stock Options”) for precombination services as well as CVRs.
The CVRs were accounted for as contingent consideration, the fair value of which was determined using a Monte Carlo simulation. Additionally, the fair value of the Replacement Stock Options was recorded as a component of consideration transferred. Finally, as a result of the Progenics Acquisition, Lantheus effectively settled an existing bridge loan with Progenics at the recorded amount (principal and accrued interest) of $10.1 million, representing the effective settlement of a preexisting relationship. This effective settlement of the bridge loan was treated as a component of consideration transferred. The Company determined that the bridge loan was at market terms and no gain or loss was recorded upon settlement.
The acquisition date fair value of the consideration transferred in the acquisition consisted of the following:
(in thousands)Amount
Issuance of common stock$398,110 
Fair value of replacement options7,125 
Fair value of bridge loan settled at close10,074 
Fair value of contingent considerations (CVRs)3,700 
Total consideration transferred(1)
$419,009 
(1)Non-cash investing and financing activities in the condensed consolidated statements of cash flows
The transaction was accounted for as a business combination which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The Company recorded a measurement period adjustment of $2.6 million related to deferred taxes for the three months ended March 31, 2021, which finalized all measurement period adjustments related to the Progenics Acquisition.
The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as measurement period adjustments made to the amounts initially recorded in June 2020. The measurement period adjustments primarily resulted from finalizing the fair values of certain intangible assets and liabilities, deferred taxes and other changes to certain tangible assets and liability accounts. Measurement period adjustments were recognized in the reporting period in which the adjustments were determined and calculated as if the accounting had been completed at the acquisition date. The related impact to net loss that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the consolidated financial statements.
15
Table of Contents
(in thousands)Amounts Recognized as of Acquisition Date
(as previously reported)		Measurement Period AdjustmentsAmounts Recognized as of Acquisition Date
(as adjusted)
Cash and cash equivalents$15,421 $— $15,421 
Accounts receivable5,787 — 5,787 
Inventory915 160 1,075 
Other current assets3,250 434 3,684 
Property, plant and equipment14,972 — 14,972 
Identifiable intangible assets (weighted average useful life):
Currently marketed product (15 years)142,100 800 142,900 
Licenses (11.5 years)87,500 (1,700)85,800 
Developed technology (9 years)3,000 (600)2,400 
IPR&D150,900 200 151,100 
Other long-term assets37,631 — 37,631 
Accounts payable(1,616)— (1,616)
Accrued expenses and other liabilities(8,207)(80)(8,287)
Other long-term liabilities(30,778)(380)(31,158)
Long-term debt and other borrowings(40,200)— (40,200)
Deferred tax liabilities(3,717)(2,258)(5,975)
Goodwill42,051 3,424 45,475 
Total consideration transferred$419,009 $— $419,009 

Intangible assets acquired consist of currently marketed products, licenses, developed technology and in-process research and development (“IPR&D”). The fair value of the acquired intangible assets was determined based on estimated future revenues, royalty rates and discount rates, among other variables and estimates. The acquired intangible assets subject to amortization were assigned useful lives based on the expected use of the assets and the regulatory and economic environment within which they are being used and are being amortized on a straight-line basis over the respective estimated useful lives. The estimated fair values of the IPR&D assets were determined based on the present values of the expected cash flows to be generated by the respective underlying assets. The Company used a discount rate of 23.0% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.
As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics, related to a prior sale of certain intellectual property. The estimated fair value of the acquired contingent receivable of $10.1 million was determined by applying a probability adjusted discounted cash flow model based on estimated future expected payments and recorded in other long-term assets.
The goodwill recognized is attributable to future technologies that are not separately identifiable that could potentially add to the currently developed and pipeline products and Progenics’ assembled workforce. Future technologies did not meet the criteria for recognition separately from goodwill because they are part of the future development and growth of the business. Goodwill of $45.5 million recognized in connection with the acquisition is not deductible for tax purposes.
The Company recognized $1.6 million and $10.5 million of acquisition-related costs, including legal, accounting, compensation arrangements and other related fees that were expensed when incurred in the three and nine months ended September 30, 2020, respectively. These costs are recorded in general and administrative expenses in the condensed consolidated statements of operations.
Progenics Pro Forma Financial Information
Progenics has been included in the Company’s consolidated financial statements since the acquisition date. Progenics contributed revenues of $5.9 million and $6.9 million, as well as a net loss of $12.6 million and $15.8 million to the Company’s condensed consolidated statements of operations for the three and nine months ended September 30, 2020, respectively.
The following unaudited pro forma financial information presents the Company’s results as if the Progenics Acquisition had occurred on January 1, 2019:
16
Table of Contents

Nine Months Ended
September 30, 2020
(in thousands)Amount
Pro forma revenue$256,163 
Pro forma net loss27,143 
The unaudited pro forma financial information for all periods presented adjusts for the effects of material business combination items, including amortization of acquired intangible assets, transaction-related costs, adjustments to interest expense related to the assumption of long-term debt, retention and severance bonuses and the corresponding income tax effects of each. These pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the operating results of the Company that would have been achieved had the Progenics Acquisition actually taken place on January 1, 2019. In addition, these results are not intended to be a projection of future results and do not reflect events that may occur after the Progenics Acquisition, including, but not limited to, revenue enhancements, cost savings or operating synergies that the combined company may achieve as a result of the Progenics Acquisition.
9. Sale of Puerto Rico Subsidiary
During the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021.
The purchase price for the stock sale was $18.0 million in cash, which includes a holdback amount of $1.8 million to be due to the Company in January 2022; the purchase price also included a working capital adjustment. The SPA contains customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA.
As part of the transaction, the Company and the buyer also entered into a customary transition services agreement and a long-term supply contract under which the Company will supply the buyer with certain of the Company’s products on commercial terms and under which the buyer has agreed to certain product minimum purchase commitments.
The Company does not believe this sale of certain net assets, reported as held for sale in the international segment prior to the change in segments in the first quarter of 2021, constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction is not classified as discontinued operations in the Company’s accompanying condensed consolidated financial statements.
The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale) and held for sale as of December 31, 2020:
17
Table of Contents
(in thousands)January 29, 2021December 31, 2020
Current Assets:
Cash and cash equivalents$540 $941 
Accounts receivable, net1,959 2,191 
Inventory530 420 
Other current assets65 43 
Total current assets3,094 3,595 
Non-Current Assets:
Property, plant & equipment, net780 761 
Intangibles, net96 96 
Other long-term assets774 790 
Total assets held for sale$4,744 $5,242 
Current Liabilities:
Accounts payable$185 $224 
Accrued expense and other liabilities369 661 
Total current liabilities554 885 
Non-Current Liabilities:
Asset retirement obligations306 302 
Other long-term liabilities588 606 
Total liabilities held for sale$1,448 $1,793 

The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income in the condensed consolidated statements of operations for the nine months ended September 30, 2021.
10. Asset Retirement Obligations
The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts site. As of September 30, 2021, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.4 million.
The Company previously operated a production facility which manufactured and processed radioactive materials at its San Juan, Puerto Rico sites.site. As of December 31, 2020, the liability for the San Juan, Puerto Rico site was recorded in liabilities held for sale and the sale was consummated on January 29, 2021.
The following table provides a summary of the changes in the Company’s asset retirement obligations:
(in thousands)Amount
Balance at January 1, 2021$14,020 
Accretion expense1,165 
Balance at September 30, 2021$15,185 
The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts production facility upon closure, although the Company does not intend to closeclose the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond.
11. Intangibles, Net
Intangibles, net, consisted of the following:
18
Table of Contents
September 30, 2021
(in thousands)Amortization MethodCostAccumulated AmortizationNet
TrademarksStraight-Line$13,540 $(11,372)$2,168 
Customer relationshipsAccelerated96,923 (94,461)2,462 
Currently marketed productsStraight-Line275,700 (17,275)258,425 
LicensesStraight-Line85,800 (9,668)76,132 
Developed technologyStraight-Line2,400 (344)2,056 
IPR&DN/A15,640 — 15,640 
   Total$490,003 $(133,120)$356,883 


December 31, 2020
(in thousands)Amortization MethodCostAccumulated AmortizationNet
TrademarksStraight-Line$13,540 $(10,958)$2,582 
Customer relationshipsAccelerated96,865 (93,770)3,095 
Currently marketed productStraight-Line142,900 (5,053)137,847 
LicensesStraight-Line85,800 (4,008)81,792 
Developed technologyStraight-Line2,400 (144)2,256 
IPR&DN/A148,440 — 148,440 
   Total$489,945 $(113,933)$376,012 


The fair valueCompany recorded amortization expense for its intangible assets of a liability$8.4 million and $4.8 million for the three months ended September 30, 2021 and 2020, respectively, and $19.1 million and $6.1 million for the nine months ended September 30, 2021 and 2020, respectively.
In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset retirement obligations isof $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset.
The below table summarizes the estimated aggregate amortization expense expected to be recognized inon the period in which the liability is incurred. above intangible assets:
(in thousands)Amount
Remainder of 2021$8,370 
202233,233 
202332,634 
202432,563 
202532,508 
2026 and thereafter201,935 
   Total$341,243 
19
Table of Contents
12. Long-Term Debt, Net, and Other Borrowings
As of September 30, 2017,2021, the liability is measured atCompany’s maturities of principal obligations under its long-term debt and other borrowings are as follows:
(in thousands)Amount
Remainder of 2021$2,500 
202211,250 
202315,000 
2024148,750 
Total principal outstanding177,500 
Unamortized debt discount(548)
Unamortized debt issuance costs(473)
Finance lease liabilities618 
Total177,097 
Less: current portion(10,356)
Total long-term debt, net and other borrowings$166,741 


At September 30, 2021, the present value ofCompany’s interest rate under the obligation expected to be incurred, of approximately $26.9 million, and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying values of the related long-lived assets and depreciated over the assets’ useful lives.
The following table provides a summary of the changes in the Company’s asset retirement obligations:
(in thousands)Amount
Balance at January 1, 2017$9,370
Accretion expense781
Balance at September 30, 2017$10,151
8. Financing Arrangementsfive-year secured term loan facility, which matures on June 30, 2024 (the “2019 Term Facility”) was 2.1%.
On March 30, 2017,31, 2021, the Company refinanced its previous $365voluntarily repaid in full the entire outstanding principal on the original $50.0 million seven-year term loan agreement (the facility thereunder, the “2015 Term Facility”“Royalty-Backed Loan”) with a new five-year $275 million term loan facility (the “2017 Term Facility” andfund managed by HealthCare Royalty Partners III, L.P. in the loans thereunder, the “Term Loans”). In addition, the Company replaced its previous $50.0 million five-year asset based loan facility (the “ABL Facility”) with a new $75.0 million five-year revolving credit facility (the “2017 Revolving Facility” and, together with the 2017 Term Facility, the “2017 Facility”). The terms of the 2017 Facility are set forth in that certain Amended and Restated Credit Agreement, dated as of March 30, 2017 (the “Credit Agreement”), by and among Holdings, the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent. The 2017 Term Facility was issued net of a $0.7 million discount. The Company has the right to request an increase to the 2017 Term Facility or request the establishment of one or more new incremental term loan facilities, in an aggregate principal amount of up to $75.0$30.9 million, plus additional amounts, in certain circumstances.

The net proceeds of the 2017 Term Facility, together with approximately $15.3 million of cash on hand, were used to refinance in full the aggregate remaining principalwhich included a prepayment amount of $0.5 million, and terminated the loans outstanding underagreement governing the 2015 Term Facility and pay related interest, transaction fees and expenses. No amounts were outstanding under the ABL Facility at that time. The Company accounted for the refinancing as both a debt extinguishment and debt modification by evaluating the refinancing on a creditor by creditor basis.Royalty-Backed Loan. The Company recorded a lossgain on extinguishment of debt of $2.2$0.9 million related to the write-off of an unamortized debt issuance costs and incurred general and administrative expenses of $1.7 million relatedpremium offset by the prepayment amount.

13. Derivative Instruments
The Company uses interest rate swaps to third-party costsreduce the variability in cash flows associated with a portion of the modifiedCompany’s forecasted interest payments on its variable rate debt. In addition,March 2020, the Company incurred and capitalized $1.6entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps is approximately 0.82%. This agreement involves the receipt of new debt issuance costs related tofloating rate amounts in exchange for fixed rate interest payments over the refinancing.
2017 Term Facility
life of the agreement without an exchange of the underlying principal amount. The Term Loans underinterest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the 2017 Term Facility bear interest with pricing based from time to time atrate swaps are recorded on the Company’s electioncondensed consolidated balance sheets at (i) LIBOR plus a spread of 4.50% or (ii) the Base Rate (as definedfair value, and changes in the Credit Agreement) plus a spreadfair value of 3.50%. Interest is payable (i) with respectthe swap agreements are recorded to LIBOR Term Loans, at the end of each Interest Period (as definedother comprehensive loss and reclassified to interest expense in the Credit Agreement) and (ii) with respect to Base Rate Term Loans, atperiod during which the end of each quarter.hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur. At September 30, 2017, the Company’s interest rate under the 2017 Term Facility was 5.7%.
The Company is permitted to voluntarily prepay the Term Loans, in whole or in part. The 2017 Term Facility requires the Company to make mandatory prepayments2021, accumulated other comprehensive loss included $0.7 million of the outstanding Term Loans in certain circumstances. The 2017 Term Facility amortizes at 1.00% per year until its June 30, 2022 maturity date.
The Company’s maturities of principal obligations under the 2017 Term Facility are as follows as of September 30, 2017:
(in thousands)Amount
Remainder of 2017$688
20182,750
20192,750
20202,750
20212,750
2022261,937
Total principal outstanding273,625
Unamortized debt discount(2,273)
Unamortized debt issuance costs(3,079)
Total268,273
Less: current portion(2,750)
Total long-term debt$265,523
2017 Revolving Facility
Under the terms of the 2017 Revolving Facility, the lenders thereunder agreed to extend credit to the Company from time to time until March 30, 2022 (the “Revolving Termination Date”) consisting of revolving loans (the “Revolving Loans” and, together with the Term Loans, the “Loans”) in an aggregate principal amount not to exceed $75.0 million (the “Revolving Commitment”) at any time outstanding. The 2017 Revolving Facility includes a $20.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”). The Letters of Credit and the borrowings under the 2017 Revolving Facilitypre-tax deferred losses that are expected to be used for working capital and other general corporate purposes.reclassified to earnings during the next 12 months.
The Revolving Loans underfollowing table presents the 2017 Revolving Facility bear interest, with pricing based from time to time at the Company’s election at (i) LIBOR plus a spreadlocation and fair value amounts of 3.50% or (ii) the Base Rate (as definedderivative instruments reported in the Credit Agreement) plus a spreadcondensed consolidated balance sheets:
(in thousands)September 30, 2021December 31, 2020
Derivatives typeClassification
Liabilities:
   Interest rate swapAccrued expenses and other liabilities$766 $1,908 
14. Accumulated Other Comprehensive Loss
The components of 2.50%. The 2017 Revolving Facility also includes an unused line fee, which is set at 0.375% whileaccumulated other comprehensive loss, net of tax of $0.2 million and $0.5 million for the Company’s secured leverage ratio (as defined in the Credit Agreement) is greater than 3.00 to 1.00 and 0.25% when the Company’s secured leverage ratio is less than or equal to 3.00 to 1.00.
The Company is permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans and Letters of Credit exceeds the total Revolving Commitment, the Company must prepay the Revolving Loans in an amount equal to such excess. As ofnine months ended September 30, 2017, there were no outstanding borrowings under the 2017 Revolving Facility.

2017 Facility Covenants
The 2017 Facility contains a number of affirmative, negative, reporting2021 and financial covenants, in each case subject to certain exceptions and materiality thresholds. The 2017 Facility requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum consolidated leverage ratio permitted by the financial covenant is displayed in the table below:
2017 Facility Financial Covenant
Period
Consolidated
Leverage Ratio
Q3 2017 through Q1 20185.00 to 1.00
Q2 2018 through Q1 20194.75 to 1.00
Thereafter4.50 to 1.00
The 2017 Facility contains usual and customary restrictions on the ability2020, respectively, consisted of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise disposefollowing:
20
Table of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.Contents
Upon an event of default, the administrative agent under the Credit Agreement will have the right to declare the Loans and other obligations outstanding immediately due and payable and all commitments immediately terminated or reduced.
(in thousands)Foreign currency translationUnrealized loss on cash flow hedgesAccumulated other comprehensive loss
Balance at January 1, 2021$(630)$(1,418)$(2,048)
Other comprehensive income before reclassifications55 312 367 
Amounts reclassified to earnings— 539 539 
Balance at September 30, 2021$(575)$(567)$(1,142)
Balance at January 1, 2020$(960)$— $(960)
Other comprehensive loss before reclassifications(9)(1,784)(1,793)
Amounts reclassified to earnings— 243 243 
Balance at September 30, 2020$(969)$(1,541)$(2,510)
The 2017 Facility is guaranteed by Holdings and Lantheus MI Real Estate, LLC (“LMI-RE”), and obligations under the 2017 Facility are generally secured by first priority liens over substantially all of the assets of each of LMI, Holdings and LMI-RE (subject to customary exclusions set forth in the transaction documents) owned as of March 30, 2017 or thereafter acquired.
9.15. Stock-Based Compensation
The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations:
         
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021202020212020
Cost of goods sold$144 $864 $1,672 $2,127 
Sales and marketing684 621 1,726 1,268 
General and administrative2,330 1,926 6,641 5,735 
Research and development709 581 1,733 1,322 
Total stock-based compensation expense$3,867 $3,992 $11,772 $10,452 
16. Leases
Operating and finance lease assets and liabilities are as follows:
(in thousands)ClassificationSeptember 30,
2021		December 31,
2020
Assets
OperatingOther long-term assets$8,287 $18,441 
FinanceProperty, plant and equipment, net508 525 
Total leased assets$8,795 $18,966 
Liabilities
Current                     
     OperatingAccrued expenses and other liabilities$1,397 $1,164 
     FinanceCurrent portion of long-term debt and other borrowings356 249 
Noncurrent
     OperatingOther long-term liabilities16,391 17,501 
     FinanceLong-term debt, net and other borrowings262 246 
Total leased liabilities$18,406 $19,160 
21
Table of Contents
 Three Months Ended
September 30,
Nine Months Ended
September 30,
(in thousands)2017 2016 2017 2016
Cost of goods sold$198
 $120
 $514
 $259
Sales and marketing183
 123
 474
 251
General and administrative1,089
 487
 2,315
 1,065
Research and development187
 147
 461
 294
Total stock-based compensation expense$1,657
 $877
 $3,764
 $1,869
IncreaseThe Company leases office space in Shares Reserved Under the 2015 Equity Incentive Plan
AtWorld Trade Center in New York City. In the Company’s annual meetingthird quarter of stockholders, held2021, the Company negotiated a sublease agreement with an unrelated third party that was signed on April 27, 2017October 11, 2021 (the “Annual Meeting”“Sublease”), and has a term of nine years, which represents the Company’s stockholders approvedremaining term of the WTC lease. Both the WTC lease and the Sublease are classified by the Company as operating leases. As a result of the negotiations of the Sublease, the Company determined that an amendmentimpairment triggering event had occurred. Accordingly, the Company performed an undiscounted cash flow analysis related to the 2015 Equity Incentive Plan to increaseasset group as of September 30, 2021. Based on the number of shares of common stock reserved for issuance thereunder by 1,200,000 shares, to an aggregate of 5,755,277 shares.
Employee Stock Purchase Plan
Atundiscounted cash flow analysis, the Annual Meeting,Company determined that the Company’s stockholders also approvedasset group, including the 2017 Employee Stock Purchase Plan (“2017 ESPP”), which authorizedROU asset, had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the issuance of up to 250,000 shares of common stock thereunder. Under the termsfair value of the 2017 ESPP, eligible U.S. employees can elect to acquire sharesasset group based on its discounted cash flows. The carrying value exceeded the fair value and, as a result, the Company recorded a non-cash impairment of $9.5 million for the Company’s common stock through periodic payroll deductions during a seriesthree and nine months ended September 30, 2021 in general and administrative expenses in the condensed consolidated statements of six month offering periods, which will generally begin in March and September of each year. Purchases under the 2017 ESPP are effected on the last business day of each offering period at a 15% discount to the closing price on that day. The 2017 ESPP was implemented, subject to stockholder approval, on March 10, 2017, and the first purchases thereunder were made on September 13, 2017.operations.

10.17. Net IncomeLoss Per Common Share
BasicA summary of net incomeloss per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted-average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.presented below:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands, except per share amounts)2021202020212020
Net loss$(13,415)$(6,386)$(31,064)$(10,061)
Basic weighted-average common shares outstanding67,623 66,820 67,409 49,858 
Basic and diluted loss per common share$(0.20)$(0.10)$(0.46)$(0.20)
Antidilutive securities excluded from diluted net income per common share3,051 2,588 3,051 1,657 
 Three Months Ended
September 30,
Nine Months Ended
September 30,
(in thousands, except per share amounts)2017 2016 2017 2016
Net income$8,526
 $4,220
 $26,259
 $21,893
Basic weighted-average common shares outstanding37,393
 31,221
 37,174
 30,658
Effect of dilutive stock options318
 1,084
 371
 391
Effect of dilutive restricted stock awards1,410
 97
 1,426
 —
Diluted weighted-average common shares outstanding39,121
 32,402
 38,971
 31,049
Basic income per common share outstanding$0.23
 $0.14
 $0.71
 $0.71
Diluted income per common share outstanding$0.22
 $0.13
 $0.67
 $0.71
        
Antidilutive securities excluded from diluted income per common share322
 448
 378
 1,873
11.18. Other Loss (Income) Expense
Other loss (income) expense consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021202020212020
Foreign currency losses (gains)$127 $(33)$156 $187 
Tax indemnification loss (income), net3,823 (555)3,092 (1,664)
Interest income(11)(7)(39)(221)
Other1 (1)— (4)
Total other loss (income)$3,940 $(596)$3,209 $(1,702)
19. Commitments and Contingencies
 Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands)2017 2016 2017 2016
Foreign currency (gains) losses$(414) $349
 $(554) $330
Tax indemnification income(489) (196) (1,469) (632)
Other income(5) (5) (14) (15)
Total other (income) expense$(908) $148
 $(2,037) $(317)
12. Legal Proceedings and Contingencies
From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company.Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.
As of September 30, 2017,2021, the Company has nohad the following material ongoing litigation in which the Company was a partyparty:
RELISTOR European Opposition Proceedings
22
Table of Contents
In October 2015, Progenics received notices of opposition to 3 European patents relating to methylnaltrexone: EP1615646, EP2368553 and EP2368554. Notices of opposition were filed separately at the European Patent Office (the “EPO”) by each of Actavis Group PTC ehf and Fresenius Kabi Deutschland GmbH. Between May 11, 2017 and July 4, 2017, the Opposition Division of the EPO (the “Opposition Division”) provided notice that the 3 European patents would be revoked. Each of these matters was appealed to the Appeal Board of the EPO. On November 13, 2020, Progenics withdrew the appeal for EP2368553 and EP2368554. Notices of termination of the proceedings with revocation of the patent were issued on November 23, 2020 for both patents.
Progenics continued its appeal for the revocation of the third patent, EP1615646. Oral proceedings for EP1615646 were held at the Appeal Board of the EPO on September 22, 2020. The revocation decision under appeal was set aside and the case was remitted to the Opposition Division for further prosecution. An oral hearing was held before the Opposition Division on September 27, 2021. The parties are awaiting the final written decision of the Opposition Division. The final written decision of the Opposition Division is appealable to the Appeal Board of the EPO by either party. Because the outcome of opposition and appeal proceedings at the EPO is uncertain, the Company cannot predict how or any material ongoing regulatorywhen this matter will ultimately be resolved.
German PSMA-617 Litigation
On November 8, 2018, Molecular Insight Pharmaceuticals, Inc., a subsidiary of Progenics (“MIP”), filed a complaint against the University of Heidelberg (the “University”) in the District Court in Mannheim, Germany (the “German District Court”). In this Complaint, MIP claimed that the discovery and development of PSMA-617 was related to work performed under a research collaboration sponsored by MIP. MIP alleged that the University breached certain contracts with MIP and that MIP is the co-owner of inventions embodied in certain worldwide patent filings related to PSMA-617 that were filed by the University. On February 27, 2019, Endocyte, Inc., a wholly owned subsidiary of Novartis AG, filed a motion to intervene in the German litigation. Endocyte is the exclusive licensee of the patent rights that are the subject of the German proceedings.
On November 27, 2018, MIP requested that the EPO stay the examination of a certain European Patent and related Divisional Applications, pending a decision from the German District Court on MIP’s Complaint. On December 10, 2018, the EPO granted MIP’s request and stayed the examination of the patent and patent applications effective November 27, 2018. MIP filed a Confirmation of Ownership with the United States Patent and Trademark Office (“USPTO”) in corresponding U.S. patent applications (U.S. Serial Nos. 15/131,118; 15/805,900; 16/038,729, 16/114,988, 16/510,495, 16/551,198, and 17/110,558). MIP’s filing with the USPTO takes the position that, in light of the collaboration and contracts between MIP and the University, MIP is the co-owner of these pending U.S. patent applications (U.S. Serial Nos. 16/510,495, 16/551,198). On March 6, 2020, MIP filed with the USPTO a notice stating that the Power of Attorney in certain pending U.S. patent applications was signed by less than all applicants or other proceedingsowners of the applications.
On February 27, 2019, the German District Court set €0.4 million as the amount MIP must deposit with the German District Court as security in the event of an unfavorable final decision on the merits of the dispute. The German District Court held the first oral hearing in the case on August 6, 2019. The German District Court considered procedural matters and had no knowledge of any investigations by government or regulatory authorities ingranted the parties the right to make further submissions. A further oral hearing occurred July 23, 2020, during which the Company is a target that could have a material adverse effectGerman District Court heard live testimony from several witnesses, testifying on its current business.

13. Related Party Transactions
Related party expenses consistedbehalf of the following:defendants. On August 24, 2020, the German District Court issued its decision dismissing MIP’s claims, stating that MIP failed to discharge its burden of proof in the matter.
  Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands)Transaction Type2017 2016 2017 2016
Avista Capital Partners, L.P. and its affiliates*Offering costs paid on behalf of Avista pursuant to registration rights agreement$—
 $—
 $326
 $—
INC Research Holdings, Inc. (“INC”)**Pharmacovigilance services—
 293
 —
 647
VWR Scientific*Inventory supplies—
 60
 297
 245
Total related party expenses $—
 $353
 $623
 $892
* During the quarter ended September 30, 2017, Avista Capital Partners, L.P., Avista Capital Partners (Offshore), L.P. and ACP-Lantern Co-Invest, LLC (collectively, “Avista”) distributed approximately 6.3 million sharesMIP filed a Notice of common stockAppeal of the German District Court’s decision on September 24, 2020 and filed its appeal brief on November 26, 2020. The University and Endocyte each filed oppositions to MIP’s Notice of Appeal on March 12, 2021. An oral hearing for the appeal is scheduled for February 9, 2022, at the Higher Regional Court Karlsruhe. MIP is also considering its legal and procedural alternatives against the defendants in other jurisdictions and proceedings. If MIP is not successful in its appeal, it will be responsible for the German court fees and fees and disbursements of defendant’s and intervenor’s counsel, both at first instance and on appeal. Most of such fees and disbursements at first instance are covered by a cash security deposited with the German District Court. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved.
Petition for Post-Grant Review
On February 4, 2021, Advanced Accelerator Applications USA, Inc. (“AAA”) filed a petition for post-grant review of U.S. Patent No. 10,640,461 (the “’461 patent”) with the Patent Trial and Appeal Board (“PTAB”) of the USPTO. The ’461 patent is owned by MIP. In the petition, AAA challenges the patentability of claims 1, 45, and 47 of the ’461 patent under 35 U.S.C. §§ 112 and 102(a)(1). The PTAB instituted Post-Grant Review (“PGR”) proceedings on July 29, 2021. MIP’s written response to the PTAB is due by December 9, 2021. The PTAB generally issues a final written decision on the validity of the challenged claims within one year of institution of the PGR proceedings. The outcome of PGR proceedings is uncertain and the Company cannot predict whether the challenged claims 1, 45 and 47 of the ‘461 patent will be deemed to be valid or invalid.
23
Table of Contents
20. Segment Information
In the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, including the impact on the Company’s business of the acquisition of Progenics described in Notes 1 and 8, and the sale of the Puerto Rico subsidiary in the aggregate, representingfirst quarter, which resulted in a change in operating and reportable segments. The Company now operates as 1 business segment: the remainderdevelopment, manufacture and sale of their holdingsinnovative diagnostic and therapeutic agents and products that assist clinicians in the Company. The transactions were effected as distributions-in-kinddiagnosis and treatment of heart disease, cancer and other diseases. This conclusion reflects the Company’s focus on the performance of the Company’s common stock to the investors in those investment funds. As such, Avista and VWR Scientific (an entity in which Avista had an interest) are no longer related parties.
** During the year ended December 31, 2016, investment funds affiliated with Avista disposed of shares of INC common stock held by them. Asbusiness on a result, such investment funds were no longer a principal owner of INC. Related party expenses included in this table represent expenses incurred during the period under which investment funds affiliated with Avista held an investment in INC.
Amounts billed and unbilled for related parties included in accounts payable and accrued expenses are immaterial at December 31, 2016.
14. Segment Information
The Company reports two operating segments, U.S. and International, based on geographic customer base.consolidated worldwide basis. The results of thesethis operating segmentssegment are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s segments derive revenues through the manufacture, marketing, selling and distribution of medical imaging products, focused primarily on cardiovascular diagnostic imaging. All goodwill has been allocated to the U.S.chief operating segment. The Companydecision maker does not identify or allocate assets to its segments.manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.
Selected information for each operating segment is as follows:
 Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands)2017 2016 2017 2016
Revenues from external customers       
U.S.$69,579
 $62,621
 $218,706
 $192,687
International10,362
 10,442
 31,431
 34,816
Total revenues from external customers$79,941
 $73,063
 $250,137
 $227,503
Operating income       
U.S.$12,243
 $11,649
 $40,306
 $35,941
International579
 946
 2,340
 8,506
Total operating income12,822
 12,595
 42,646
 44,447
Interest expense4,442
 6,792
 14,147
 20,799
Debt retirement costs—
 1,415
 —
 1,415
Loss on extinguishment of debt—
 —
 2,161
 —
Other (income) expense(908) 148
 (2,037) (317)
Income before income taxes$9,288
 $4,240
 $28,375
 $22,550

15.21. Subsequent Events
On October 30, 2017, LMI entered into11, 2021, the Company signed a binding commercial supply arrangement pursuant to which LMI will supply Cardinal Health with TechneLite generators, Xenon, Neurolite and other products through 2018.  The supply arrangement specifies pricing levels and requires Cardinal Health to purchase minimum volumessublease for certain office space. See Note 16, “Leases”, for further details.
24
Table of certain products from LMI during certain periods.  The supply arrangement will expire on December 31, 2018 and may be terminated upon the occurrence of specified events, including a material breach by the other party and certain force majeure events.Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Note Regarding Forward-Looking Statements
Some of the statements contained in this Quarterly Report on Form 10-Q are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements, including, in particular, statements about our plans, strategies, prospects and industry estimates are subject to risks and uncertainties. These statements identify prospective information and includecan generally be identified by words such as “anticipates,” “intends,“believes,” “plans,“can,” “seeks,” “believes,“could,” “estimates,” “expects,” “should,“hopes,” “could,“intends,” “launch,” “may,” “pipeline,” “plans,” “predicts,” “hopes”“seeks,” “should,” “target,” “will,” “would” and similar expressions.expressions, or by express or implied discussions regarding potential marketing approvals or new indications for the collaborations, products candidates or approved products described in this Quarterly Report on Form 10-Q, or regarding potential future revenues from such collaborations, product candidates and products. Examples of forward-looking statements include but are not limited to, statements we make regarding: (i)relating to our outlook and expectations including, without limitation, in connection withwith: (i) the impact of the global COVID-19 pandemic on our business, financial conditions and prospects; (ii) continued market expansion and penetration for our commercial products, particularly DEFINITY, in the face of increasedsegment competition and futurepotential generic competition, including as a result of patent and regulatory exclusivity expirations; (ii) our outlook and expectations in connection with future performance of Xenon in the face of increased competition; (iii) our outlook and expectations related to our ability to maintainsuccessfully launch PYLARIFY as a commercial product, including (A) our ability to obtain FDA approval for additional PET manufacturing facilities (“PMFs”) that could manufacture PYLARIFY, (B) the ability of those PMFs to supply PYLARIFY to customers, and profitably renew(C) our key customer contracts; andability to sell PYLARIFY to customers; (iv) the global Molybdenum-99 (“Mo-99”) supply; (v) our outlook and expectations related to products manufactured at Jubilant HollisterStier (“JHS”) and global isotope supply.our modified formulation of DEFINITY (“DEFINITY RT”) to be commercially manufactured at Samsung Biologics (“SBL”), including our ability to renew, modify or replace those agreements as may be necessary; (vi) the continued integration of the Progenics products and product candidate portfolio into our business following the Progenics Acquisition; (vii) our ability to use in-house manufacturing capacity; (viii) our ability to successfully launch aPROMISE, otherwise known as PYLARIFY AI, as a commercial product; (ix) the potential reclassification by the FDA of certain of our products and product candidates from drugs to devices with the expense, complexity and potentially more limited competitive protection such reclassification could cause; (x) the efforts and timing for clinical development of our product candidates and new clinical applications for our products, in each case, that we or our strategic partners may develop, including 1095 and flurpiridaz F 18; and (xi) our ability to develop highly contextualized assessments of disease burden using artificial intelligence (“AI”). Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, such statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. SuchThese statements are neither statements of historical fact nor guarantees or assurances of future performance. The matters referred to in the forward-looking statements contained in this Quarterly Report on Form 10-Q may not in fact occur. We caution you, therefore, against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in theThese forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions and the following:
Our ability to continue to increase segment penetration for DEFINITY in suboptimal echocardiograms in the face of increased segment competition from other echocardiography contrast agents, including Optison from GE Healthcare Limited (“GE Healthcare”) and Lumason from Bracco Diagnostics Inc. (“Bracco”) and future patent and regulatory exclusivity expirations;
Risks associated with revenues and unit volumes for Xenon in pulmonary studies and the potential competition in this generic segment from Curium (formerly known as Mallinckrodt Nuclear Imaging; purchased by IBA Molecular in January 2017 and renamed Curium in April 2017);
Our dependence on key customers for our medical imaging products, and our ability to maintain and profitably renew our contracts with those key customers, including Cardinal Health (“Cardinal”), United Pharmacy Partners (“UPPI”), GE Healthcare and Triad Isotopes (“Triad”);
Our dependence upon third parties for the manufacture and supply of a substantial portion of our products, including DEFINITY at JHS;
Risks associated with the technology transfer programs to secure production of our products at alternate contract manufacturer sites, including a next generation DEFINITY product at Samsung BioLogics (“SBL”) in South Korea;
Risks associated with the manufacturing and distribution of our products and the regulatory requirements related thereto;
The instability of the global Molybdenum-99 (“Moly”) supply;
The dependence of certain of our customers upon third-party healthcare payors and the uncertainty of third-party coverage and reimbursement rates;
Uncertainties regarding the impact of on-going U.S. healthcare reform proposals on our business, including related reimbursements for our current and potential future products;
Our beingare subject to extensive government regulationa number of risks, uncertainties and our potential inability to comply withassumptions, including those regulations;
Potential liability associated with our marketing and sales practices;
The occurrence of any serious or unanticipated side effects with our products;
Our exposure to potential product liability claims and environmental liability;
Risks associated with our lead agent in development, flurpiridaz F 18, including:
▪The ability of GE Healthcare to successfully complete the Phase III development program;
▪The ability to obtain Food and Drug Administration (“FDA”) approval; and
▪The ability to gain post-approval market acceptance and adequate reimbursement;

The extensive costs, time and uncertainty associated with new product development, including further product development relying on external development partners or potentially developed internally;
Our inability to introduce new products and adapt to an evolving technology and diagnostic landscape;
Our inability to identify and in-license or acquire additional products to grow our business;
Our inability to protect our intellectual property and the risk of claims that we have infringed on the intellectual property of others;
Risks associated with prevailing economic or political conditions and events and financial, business and other factors beyond our control;
Risks associated with our international operations;
Our inability to adequately protect our facilities, equipment and technology infrastructure;
Our inability to hire or retain skilled employees and key personnel;
Risks related to our outstanding indebtedness and our ability to satisfy those obligations;
Costs and other risks associated with the Sarbanes-Oxley Act and the Dodd-Frank Act;
Our inability to utilize or limitations in our ability to utilize net operating loss carryforwards to reduce our future tax liability;
Risks related to the ownership of our common stock; and
Other factors that are described in Part I, Item 1A. “Risk Factors”1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 20162020, and in Part II—II, Item 1A. “Risk Factors” ofin this Quarterly Report on Form 10-Q.
Factors that could cause or contribute to such differences include, but are not limited to, those that are discussed in other documents we file with the SEC. Any forward-looking statement made by us in this Quarterly Report on Form 10-Q speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
InvestorAvailable Information
Our global Internet site is www.lantheus.com. We routinely make available important information, including copies of our annual, periodicAnnual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and currentamendments to those reports filed or furnished with the SEC underpursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after those reports are electronically filed with, or furnished to, the SEC, free of charge on our website at http://www.investor.lantheus.com.investor.lantheus.com. We recognize our website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with our disclosure obligations under SEC Regulation FD. Information contained on our website shall not be deemed incorporated into, or to be part of this Quarterly Report on Form 10-Q, and any website references are not intended to be made through active hyperlinks.
Our reports filed with, or furnished to, the SEC are also available on the SEC’s website at www.sec.gov, and for Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, in an iXBRL (Inline Extensible Business Reporting Language) format. iXBRL is an electronic coding language used to create interactive financial statement data over the Internet. The information on our website is neither part of nor incorporated by reference into this Quarterly Report on Form 10-Q.
25
Table of Contents
The following discussion and analysis of our financial condition and results of operations should be read together with the condensed consolidated financial statements and the related notes included in Item 1 of this Quarterly Report on Form 10-Q as well as the other factors described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 20162020, and in Part II—II, Item 1A. “Risk Factors” ofin this Quarterly Report on Form 10-Q.
Overview
Our Business
We are a globalan established leader in the development, manufacture and commercialization offully integrated provider committed to innovative diagnosticimaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find, Fight and Follow serious medical imagingconditions. Clinicians use our agents and products that assist clinicians in the diagnosisechocardiography, nuclear imaging, and treatment of cardiovascular and other diseases. Clinicians use our imaging agents and products across a range of imaging modalities, including echocardiography and nuclear imaging.oncologic therapeutics. We believe that the resulting improved diagnostic information enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improvedbetter patient outcomes, reducing patient risk and limiting overall costs for payers and the entire healthcare system.
Our commercial products are used by cardiologists, nuclear medicine physicians, radiologists, oncologists, urologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. We sell our products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices.

We produce and market our agents and products throughout the U.S., selling primarily to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. We sell our agents and products globally and have operations inoutside the U.S., Puerto Rico and through a combination of direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia PacificAsia-Pacific and Latin America.
Our Product Portfolio
Our product portfolio includes an ultrasound contrast agentIn the first quarter of fiscal year 2021, we completed the evaluation of our operating and nuclear imaging products. Our principal products includereporting structure, including the following:
DEFINITY is an ultrasound contrast agent used in ultrasound examsimpact on our business of the heart, also knownacquisition of Progenics, and the sale of our Puerto Rico subsidiary in the first quarter, which resulted in a change in our operating segments to one reportable business segment.
PYLARIFY Approval and Commercial Launch
On May 27, 2021, we announced that the FDA had approved PYLARIFY, an F 18-labeled positron emission tomography (“PET”) imaging agent targeting prostate-specific membrane antigen (“PSMA”). PYLARIFY enables the visualization of primary prostate tumors as echocardiography exams. DEFINITY contains perflutren-containing lipid microsphereswell as bone and is indicatedsoft tissue metastases, with potential high clinical utility in the detection of recurrent and/or metastatic prostate cancer. The approval of PYLARIFY was based on data from two Company-sponsored pivotal studies (“OSPREY” and “CONDOR”) designed to establish the safety and diagnostic performance of PYLARIFY across the prostate cancer disease continuum. Results from OSPREY (Cohort A) demonstrated improvement in specificity and positive predictive value of PYLARIFY PET imaging over conventional imaging in men at risk for metastatic prostate cancer prior to initial definitive therapy. CONDOR studied men with biochemical recurrent prostate cancer. In patients with biochemical recurrent prostate cancer and non-informative baseline imaging, PYLARIFY demonstrated high correct localization and detection rates, including in patients with low prostate-specific antigen (“PSA”) blood level values (median PSA 0.8 ng/mL).
Upon approval, PYLARIFY was immediately available in parts of the U.S., such as the mid-Atlantic and the South. Since its approval, PYLARIFY availability has expanded into additional regions, including six of the largest metropolitan areas in the U.S. for use- New York, Los Angeles/San Diego, Chicago, Dallas, Houston, and Washington, D.C. – as well as select locations in patientsthe Southeast, the Midwest, the Southwest, the Northeast and the Northwest. We expect PYLARIFY availability to continue to expand across the U.S. over the remainder of the year, with suboptimal echocardiogramsbroad nationwide availability anticipated by year end.
The commercial launch of PYLARIFY is complex and expensive. During 2021, we hired additional employees to assist us with the commercialization of PYLARIFY, including in imagingsales, marketing, reimbursement, quality and medical affairs. To manufacture PYLARIFY, we have assembled and are qualifying a nationwide network of PMFs with radioisotope-producing cyclotrons that make fluorine-18, which has a 110-minute half-life, so PYLARIFY is manufactured and distributed rapidly to end-users. After being made on a cyclotron at a PMF, the left ventricular chamberF 18 is then combined with certain chemical ingredients in specially designed chemistry synthesis boxes to manufacture PYLARIFY, which is then transferred to a radiopharmacist who prepares and left endocardial borderdispenses patient-specific doses of the heart in ultrasound procedures. We launched DEFINITY in 2001, andfinal product. Because each of the PMFs manufacturing these products is deemed by the FDA to be a separate manufacturing site, each has to be approved by the FDA. Although we are able to provide PYLARIFY in the U.S., its composition of matter patent will expire in 2019, its manufacturing patent will expire in 2021, and a new method of use patent will expire in 2037. In numerous foreign jurisdictions, patent protection or regulatory exclusivity will currently expire in 2019. We also have an active next generation development program for this agent including pursuing additional indications, new patent protection, and new formulations, butregions listed above, we can give no assurance that the programFDA will continue to approve PMFs in accordance with our planned roll-out schedule. If FDA approval of manufacturing sites is delayed, our future business, results of operations, financial condition and cash flows could be adversely affected.
In addition, obtaining adequate reimbursement for PYLARIFY will be successful or that additional patents will protect the agent.
TechneLite is a technetium generator which provides the essential nuclear material used by radiopharmacies to radiolabel Cardiolite, Neurolitecritical, including not only coverage from Medicare, Medicaid and other technetium-based radiopharmaceuticals used in nuclear medicine procedures. TechneLite uses Moly as its active ingredient.
Xenon is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also for imaging cerebral blood flow. Xenon is manufactured by a third-party and is processed and finished by us.
Sales of our contrast agent, DEFINITY, are made in the U.S. and Canada through our direct sales team of approximately 80 employees. In the U.S., our nuclear imaging products, including TechneLite, Xenon, Neurolite and Cardiolite, are primarily distributed through commercial radiopharmacies, the majority of which are controlled by or associated with Cardinal, UPPI, GE Healthcare and Triad. A small portion of our nuclear imaging product sales in the U.S. are made through our direct sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical capabilities. Outside the U.S., we own one radiopharmacy in Puerto Rico, where we sell our own productsgovernment payors, as well as productsprivate payors, but also appropriate payment levels, which adequately cover the
26
Table of third partiesContents
manufacturing and distribution costs associated with an F 18-based agent. We can give no assurance that pass-through status will be granted or that other adequate reimbursement can be secured to end-users.allow PYLARIFY to become successfully commercialized.
In January 2016, we sold our Canadian radiopharmacies to Isologic Innovative Radiopharmaceuticals Ltd. (“Isologic”) and entered into a supply agreement under which we supply Isologic with certain of our products on commercial terms, including certain product purchase commitments by Isologic. In August 2016, we sold our Australian radiopharmacy servicing business to Global Medical Solutions (“GMS”), and entered into a supply agreement under which we supply GMS with certain of our products on commercial terms, including certain minimum product purchase commitments by GMS.
We also maintain our own direct sales force in Canada so that we can control the importation, marketing, distribution and sale of our imaging agents in Canada. In Europe, Australia, Asia Pacific and Latin America, we rely on third-party distributors to market, sell and distribute our nuclear imaging and contrast agent products, either on a country-by-country basis or on a multi-country regional basis.
The following table sets forth our revenues derived from our principal products:
 Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands)2017 
% of
Revenues
 2016 
% of
Revenues
 2017 
% of
Revenues
 2016 
% of
Revenues
DEFINITY$37,729
 47.2% $32,604
 44.6% $115,569
 46.2% $97,499
 42.9%
TechneLite26,356
 33.0% 24,533
 33.6% 79,900
 31.9% 74,621
 32.8%
Xenon7,726
 9.6% 6,677
 9.1% 23,713
 9.5% 21,625
 9.5%
Other8,130
 10.2% 9,249
 12.7% 30,955
 12.4% 33,758
 14.8%
Total revenues$79,941
 100.0% $73,063
 100.0% $250,137
 100.0% $227,503
 100.0%

Key Factors Affecting Our Results
Our 2021 financial performance will reflect full year results of the Progenics business, whereas the prior year only incorporated results since the Closing Date. We also expect that the approval of PYLARIFY in May 2021 and subsequent launch will result in increased revenues.
Our business and financial performance have been, and continue to be, affected by the following:
COVID-19 Pandemic
The global COVID-19 pandemic has had, and may continue to have, a material impact on our business. Towards the end of the first quarter of 2020 we began to experience, and through the date of this filing we are continuing to experience, impacts to our business and operations related to the COVID-19 pandemic, including the impact of stay-at-home mandates and advisories, and a decline in the volume of certain procedures and treatments using our products.
For example, there has been a substantial reduction in pulmonary ventilation studies in which our product, Xenon, is used because of institutional concerns and professional society guidelines relating to the possible spread of COVID-19 to technicians and other patients, given that Xenon is both inhaled and exhaled by the patient. As a result, Xenon sales have decreased significantly. In March 2021, the Society of Nuclear Medicine and Medical Imaging (“SNMMI”), updated its guidance regarding in-hospital respiratory inhalation procedures administered (or performed) during the pandemic, modifying its previous position. Based on advances in testing and procedural protocols since the onset of the pandemic as well as increasing vaccination rates, SNMMI now allows that under appropriate conditions for safe administration, pulmonary ventilation studies can be performed where necessary to reach a definitive diagnosis for a patient. Notwithstanding this change in March 2021, our Xenon sales through the third quarter of 2021 continued to be at reduced levels, and we expect these reduced levels to continue for at least as long as COVID-19 precautions remain in place. We can give no assurance that Xenon sales will return to historic levels.
As a result of the COVID-19 pandemic, we undertook a thorough analysis of all our discretionary expenses. In the first quarter of 2020, we implemented certain cost reduction initiatives. For most of the second quarter of 2020, we reduced our work week from five days to four days and reduced the pay for our personnel by varying amounts, depending on level of seniority.
During the second quarter of 2020, Progenics also implemented certain cost reduction initiatives, and new enrollment in the ARROW Phase 2 study of 1095 in mCRPC patients was paused to minimize the risk to subjects and healthcare providers during the pandemic. New enrollment in that study restarted in October 2020.
GE Healthcare, our development and commercialization partner for flurpiridaz F 18, also delayed enrollment in the second Phase 3 clinical trial because of the pandemic and resumed enrollment in the third quarter of 2020.
Although some of the restrictions, including stay-at-home mandates, imposed in response to the COVID-19 pandemic have been lifted in much of the United States, and there has been a rapid rollout and development of certain vaccines, the resurgence of COVID-19 infections did impact certain aspects of our business during the third quarter of 2021 and the pandemic could still have a future negative impact on our business, particularly if there are additional resurgences as a result of mutations or other variations to the virus that increase its communicability or its impact on certain populations, geographic regions and the healthcare system, including elective procedures and hospital access.
While we are currently unable to estimate the impact of COVID-19 on our overall 2021 operations and financial results, we ended the third quarter of 2021 with $91.5 million of cash and cash equivalents. With our available liquidity and prudent expense management, we currently believe that we have sufficient financial resources to operate our business, support our customers, launch PYLARIFY as a new commercial product, and support the continued development of our product candidate pipeline, although we can give no assurances that we will have sufficient liquidity for all of these items, as the future trajectory of the pandemic is unknown and may affect our liquidity.
Anticipated Continued Growth of DEFINITY and Expansion of Our Ultrasound Microbubble Franchise
We believe the market opportunity for our contrastultrasound microbubble enhancing agent, DEFINITY, remainscontinues to be significant. DEFINITY is currentlyhas been our fastest growing and highest margin commercial product. We believe thatanticipate DEFINITY sales will continue to grow and that DEFINITY will constitute a greater share of our overall product mix.in the future. As we bettercontinue to educate the physician and healthcare provider community about the benefits and risks of this product,DEFINITY, we believe we will experience further penetration of suboptimal echocardiograms.
The future growth of our DEFINITY sales will be dependent on our abilityable to continue to increase segment penetration for DEFINITY in suboptimal echocardiograms and, as discussed below in “—Inventory Supply,” on the ability of JHS to continue to manufacture and release DEFINITY on a timely and consistent basis. See “Part II—Item 1A. Risk Factors—The growth of our business is substantially dependent on increased market penetration forgrow the appropriate use of DEFINITY in suboptimal echocardiograms.”
There are In a U.S. market with three echocardiography contrastultrasound enhancing agents approved by the FDA, for sale in the U.S.—we estimate that DEFINITY which we estimated as having approximatelyhad over 80% of the U.S. market for contrast agents in echocardiography procedures as of December 31, 2016, Optison from GE Healthcare2020.
27
Table of Contents
As we continue to pursue expanding our microbubble franchise, our activities include:
•Patents - We continue to actively pursue additional patents in connection with DEFINITY and Lumason from Bracco.DEFINITY RT, both in the U.S. and internationally. In the U.S. for DEFINITY, we now own a total of four Orange Book-listed method of use patents, one of which expires in 2035 and three of which expire in 2037, as well as additional manufacturing patents that are not Orange Book-listed expiring in 2023 and 2037. In the U.S. for DEFINITY RT, we now own a total of five Orange Book-listed patents, including a composition of matter patent which expires in 2035. Outside of the U.S., while our original DEFINITY patent protection and regulatory exclusivity have generally expired, we are currently prosecuting additional DEFINITY and DEFINITY RT patents to obtain similar patent protection as in the U.S. The Orange Book-listed patents include a patent on the use of VIALMIX RFID which expires in 2037; additional VIALMIX RFID patent applications have been submitted in major markets throughout the world.
CompetitionHatch-Waxman Act - Even though our longest duration Orange Book-listed DEFINITY patent extends until March 2037, because our Orange Book-listed composition of matter patent expired in June 2019, we may face generic DEFINITY challengers in the near to intermediate term. Under the Hatch-Waxman Act, the FDA can approve Abbreviated New Drug Applications (“ANDAs”) for Xenon
Xenon gas for lung ventilation diagnosisgeneric versions of drugs if the ANDA applicant demonstrates, among other things, that (i) its generic candidate is our third largestthe same as the innovator product by revenues. establishing bioequivalence and providing relevant chemistry, manufacturing and product data, and (ii) the marketing of that generic candidate does not infringe an Orange Book-listed patent or that an Orange Book-listed patent is invalid. With respect to any Orange Book-listed patent covering the innovator product, the ANDA applicant must give a notice to the innovator (a “Notice”) that the ANDA applicant certifies that its generic candidate will not infringe the innovator’s Orange Book-listed patent or that the Orange Book-listed patent is invalid. The innovator can then challenge the ANDA applicant in court within 45 days of receiving that Notice, and FDA approval to commercialize the generic candidate will be stayed (that is, delayed) for up to 30 months (measured from the date on which a Notice is received) while the patent dispute between the innovator and the ANDA applicant is resolved in court. The 30-month stay could potentially expire sooner if the courts determine that no infringement had occurred or that the challenged Orange Book-listed patent is invalid or if the parties otherwise settle their dispute.
As of the date of filing of this Quarterly Report on Form 10-Q, we have not received any Notice from an ANDA applicant. If we were to (i) receive any such Notice in the future, (ii) bring a patent infringement suit against the ANDA applicant within 45 days of receiving that Notice, and (iii) successfully obtain the full 30-month stay, then the ANDA applicant would be precluded from commercializing a generic version of DEFINITY prior to the expiration of that 30-month stay period and, potentially, thereafter, depending on how the patent dispute is resolved. Solely by way of example and not based on any knowledge we currently have, if we received a Notice from an ANDA applicant in November 2021 and the full 30-month stay was obtained, then the ANDA applicant would be precluded from commercialization until at least May 2024. If we received a Notice some number of months in the future and the full 30-month stay was obtained, the commercialization date would roll forward in the future by the same calculation.
•DEFINITY RT - In orderNovember 2020, the FDA approved our supplemental new drug application (“sNDA”) for DEFINITY RT. DEFINITY RT is a modified formulation of DEFINITY that allows both storage and shipment at room temperature (DEFINITY’s previously approved formulation requires refrigerated storage). The modified formulation provides clinicians an additional choice and allows for greater utility of this formulation in broader clinical settings. We believe DEFINITY RT will become commercially available in the fourth quarter of 2021, although that timing cannot be assured. Given its physical characteristics, we believe DEFINITY RT is also well-suited for inclusion in kits requiring microbubbles for other indications and applications (including in kits developed by third parties of the type described in the paragraph entitled Additional Clinical Applications below).
•Vialmix RFID – In August 2020, we announced the FDA approved our sNDA for our next-generation activation device designed specifically for both DEFINITY and DEFINITY RT. The activation rate and time are controlled by VIALMIX RFID through the use of radio-frequency identification technology (“RFID”) to increaseensure reproducible activation of DEFINITY and DEFINITY RT. The RFID tag, which is affixed to the predictabilityvial label, enables the DEFINITY or DEFINITY RT vial to be appropriately activated when utilized with the VIALMIX RFID activation device. We believe VIALMIX RFID will become available in the fourth quarter of 2021, although that timing cannot be assured.
•Additional Clinical Applications - As we continue to look for other opportunities to expand our microbubble franchise, we are evaluating new indications and clinical applications beyond echocardiography and ultrasound enhancing agent imaging generally. Prior to 2021, we entered into the following collaborations: (i) Cerevast Medical, Inc. (“Cerevast”) in which our microbubble will be used in connection with Cerevast’s ocular ultrasound device to improve blood flow in occluded retinal veins in the eye; (ii) CarThera SAS (“CarThera”) for the use of our Xenon business,microbubbles in combination with SonoCloud, a proprietary implantable device in development for the treatment of recurrent glioblastoma; and (iii) Insightec Ltd. (“Insightec”) which will use our microbubbles in connection with the development of Insightec’s transcranial guided focused ultrasound device for the treatment of glioblastoma as well as other neurodegenerative conditions. In April 2021, we announced a strategic collaboration with Allegheny Health Network (“AHN”) which will use our microbubbles in combination with AHN’s ultrasound-assisted non-viral gene transfer technology for the development of a proposed treatment
28
Table of Contents
of xerostomia. Xerostomia is a lack of saliva production leading to dry mouth and has a variety of causes, including radiotherapy and chemotherapy, the chronic use of drugs and rheumatic and dysmetabolic diseases.
•In-House Manufacturing - We have entered into Xenoncompleted construction of specialized, in-house manufacturing capabilities at our North Billerica, Massachusetts facility for DEFINITY and, potentially, other sterile vial products. We believe this investment will allow us to better control DEFINITY manufacturing and inventory, reduce our costs in a potentially more price competitive environment, and provide us with supply chain redundancy. We have filed our sNDA with the FDA and currently expect to have DEFINITY manufactured at this facility commercially available in early 2022, although the approval of our sNDA and that timing cannot be assured.
•DEFINITY in China - In March 2020, in connection with our Chinese development and distribution arrangement with Double-Crane Pharmaceutical Company (“Double-Crane”), we filed an Import Drug License application with the National Medical Products Administration, or the NMPA, for the use of DEFINITY for the echocardiography indication. We believe this is an important milestone in our efforts to commercialize DEFINITY in China. Double-Crane is also in the process of analyzing the clinical results relating to the liver and kidney indications and will also work with us to prepare an Import Drug License application for those indications.
Global Mo-99 Supply
We currently have Mo-99 supply agreements with customers at committed volumesInstitute for Radioelements (“IRE”), running through December 31, 2022, with auto-renewal provisions subject to notice of non-renewal, and reduced prices. These stepswith NTP Radioisotopes (“NTP”) and the Australian Nuclear Science and Technology Organisation (“ANSTO”), running through December 31, 2021, and for which we are currently negotiating an extension. We also have a Xenon supply agreement with IRE which runs through June 30, 2022, and which is subject to further extension.
Although we have a globally diverse Mo-99 supply with IRE in Belgium, NTP in South Africa, and ANSTO in Australia, we still face supplier and logistical challenges in our Mo-99 supply chain. The NTP processing facility had periodic outages in 2017, 2018 and 2019. When NTP was not producing, we relied on Mo-99 supply from both IRE and ANSTO to limit the impact of the NTP outages. In 2019 and 2020, ANSTO experienced multiple facility issues that resulted in more predictable Xenon unit volumes. Historically, several companies, including Mallinckrodt Nuclear Imaging (now known as Curium), sold packaged Xenon as a pulmonary imaging agentANSTO outages and volume limitations, during which time we relied on IRE and NTP to limit the impact of those outages and limitations. Because of the COVID-19 pandemic, we experienced challenges receiving regularly scheduled orders of Mo-99 from our global suppliers, particularly in the U.S., but from 2010 through the firstsecond quarter of 2016,2020. We continue to manage these various supply chain challenges, but depending on reactor and processor schedules and operations, at times we werehave not been able to fill some or all of the only supplierdemand for our TechneLite generators on certain manufacturing days. A prolonged disruption of this imaging agent in the U.S. In March 2016, Mallinckrodt Nuclear Imaging received regulatory approvalservice from the FDA to again sell packaged Xenon in the U.S. Depending upon the pricing, extent of availability and market penetration of such offering, we believe we are at risk for volume loss and price erosion for those customers which are not subject to price or volume commitments with us. See Part I, Item 1A. “Risk Factors —We face potential supply and demand challenges for Xenon”one of our Annual Reportthree Mo-99 processing sites or one of their main Mo-99-producing reactors could have a substantial negative effect on Form 10-Kour business, results of operations, financial condition and cash flows.
We are also pursuing additional sources of Mo-99 from potential new producers to further augment our current supply. In November 2014, we entered into a strategic arrangement with SHINE Medical Technologies LLC (“SHINE”) for the year ended December 31, 2016.future supply of Mo-99. Under the terms of the supply agreement, SHINE will provide Mo-99 produced using its proprietary LEU-solution technology for use in our TechneLite generators once SHINE’s facility becomes operational and receives all necessary regulatory approvals, which SHINE now estimates will occur in late 2022. However, we cannot assure you that SHINE or any other possible additional sources of Mo-99 will result in commercial quantities of Mo-99 for our business, or that these new suppliers together with our current suppliers will be able to deliver a sufficient quantity of Mo-99 to meet our needs.
Inventory Supply
We obtain a substantial portion of our imaging agents from a third-party suppliers.supplier. JHS is currently our sole source manufacturer of DEFINITY, Neurolite,NEUROLITE, Cardiolite and evacuation vials, the latter being an ancillary component for our TechneLite generators. We are currently seeking approval from certain foreign regulatory authorities for JHS to manufacture certain of our products. Until we receive these approvals, we will face continued limitations on where we can sell those products outside of the U.S.
In addition to JHS, we are also currently workingrely on SBL as our sole source manufacturer of DEFINITY RT. Our manufacturing agreement with JHS relating to secure additional alternative suppliers forDEFINITY expires in February 2022, and our key products as partmanufacturing agreements relating to NEUROLITE and Cardiolite expire in December 2023, in each case, with auto-renewal provisions subject to notice of non-renewal. On July 27, 2021, we received a letter from JHS that it was providing notice of non-renewal of our ongoing supply chain diversification strategy.manufacturing agreement relating to DEFINITY, but that JHS remained interested in negotiating a new agreement. We have on-going development and technology transfer activitiesare actively negotiating a new manufacturing agreement with JHS for a next generation DEFINITY, product with SBL, whichalthough there is located in South Korea, butno assurance that we cannot give any assurances as to if and when those technology transfer activities will be completed and whenable to reach an agreement on mutually acceptable terms or at all. In the event we will beginare not able to receive supply of a next generation DEFINITY product from SBL. See Part I, Item 1A. “Risk Factors—Our dependence upon third parties for the manufacture and supply of a substantial portion of our products could prevent us from delivering our products to our customers in the required quantities, within the required timeframes,enter into an agreement on mutually acceptable terms or at all, we expect that we would exercise our right under our current agreement with JHS to request a terminal supply of DEFINITY in an amount sufficient to meet our supply needs for DEFINITY until our in-house manufacturing facility is operational and producing enough DEFINITY to meet our supply needs, although there is no assurance that there would be no disruption.
29
Table of Contents
We have completed construction of specialized, in-house manufacturing capabilities at our North Billerica, Massachusetts facility for DEFINITY and, potentially, other sterile vial products, which could resultwill also allow us to optimize our costs and reduce our supply chain risk, including in order cancellationsthe event we cannot enter into a new agreement with JHS for DEFINITY as noted above. We have filed our sNDA with the FDA and decreased revenues”currently expect to have DEFINITY manufactured at this facility commercially available in early 2022, although the approval of our Annual Report on Form 10-K for the year ended December 31, 2016.sNDA and that timing cannot be assured.
Radiopharmaceuticals are decaying radioisotopes with half-lives ranging from a few hours to several days. These products cannot be kept in inventory because of their limited shelf lives and are subject to just-in-time manufacturing, processing and distribution, which takes place at our facilities in North Billerica, Massachusetts facility.and Somerset, New Jersey.
Global Isotope SupplyIntegration of the Progenics Acquisition
We currently have Moly supply agreementsOn June 19, 2020, we completed the Progenics Acquisition. Progenics’ portfolio of products and product candidates included, among other things, therapeutic agents designed to target cancer (AZEDRA, 1095 and PSMA TTC), diagnostic imaging agents designed to target PSMA for prostate cancer (PYLARIFY and 1404), RELISTOR for opioid-induced constipation, AI imaging technologies and leronlimab being developed for HIV infection. Progenics’ revenue was generated from two principal sources: first, royalties and development and commercial milestones from strategic partnerships, including royalties from Bausch Health Companies, Inc. (“Bausch”) from sales of RELISTOR; and second, AZEDRA sales.
The ultimate success of the Progenics Acquisition will depend on our ability to successfully combine the business of Progenics with NTP Radioisotopes (“NTP”)our own and realize the anticipated benefits, including synergies, cost savings, innovation and operational efficiencies and revenue growth from the acquisition.
Our combined business is now larger and significantly more complex than our business was immediately prior to the consummation of South Africathe Progenics Acquisition. Our ability to successfully manage this combined business will depend upon our ability to continue to integrate and ANSTO of Australia,manage the combined business with its increased scale and with Institute for Radioelements (“IRE”) of Belgium, each running through December 31, 2017,scope, and a Xenon supply agreement with IRE which runs through June 30, 2019, subject to extensions.

We believe we are well-positioned with ANSTO, IREincreased costs and NTP to have a secure supply of Moly, including low-enriched uranium-based Moly produced from targets containing less than 20% of Uranium-235 (“LEU Moly”). From November 2016, the NRU reactor transitioned from providing regular supply of medical isotopes to providing only emergency back-up supply of highly-enriched uranium-based Moly through March 2018. ANSTO has already significantly increased its Moly production capacity from its existing facility in August 2016 and has under construction, in cooperation with NTP, a new Moly processing facility that ANSTO believes will expand its production capacity, which is expected to be in commercial operation in the first half of 2018.complexity. In addition, IRE received approval from its regulator to expand its production capability by up to 50% of its former capacity. The new ANSTOthe CVRs issued as partial consideration for the Progenics Acquisition create additional operational obligations and IRE production capacity is expected to replace and exceed what was the NRU’s most recent routine production.
We are receiving bulk unprocessed Xenon from IRE, which we are processing and finishing for our customers. We believe we are well-positioned to supply Xenon to our customers.accounting complexity. See Part I,II, Item 1A. “Risk Factors —We face potential supply- The CVRs we issued as part of the Progenics Acquisition may result in substantial future payments and demand challenges for Xenon”could divert the attention of our Annual Report on Form 10-Kmanagement; in addition, the actual payments made in connection with the CVRs, if any, may not be consistent with the estimated fair value of the CVRs that we are required to prepare for the year ended December 31, 2016.
Demand for TechneLite
We believe that due to industry-wide cost containment initiatives that have resulted in a transition of where imaging procedures are performed, from free-standing imaging centers to the hospital setting, the total MPI market has been essentially flat since 2011. Our 2016 sales of TechneLite generators exceeded our expectations because of opportunistic sales when customers could not obtain sufficient generators from other suppliers.accounting purposes.” We can give no assurancesassurance that such opportunistic salesthe actual amounts paid, if any, in connection with the CVRs will be replicated in 2017.
In November 2016, CMS announced the 2017 final Medicare payment rules for hospital outpatient settings. Under the final rules, each technetium dose produced from a generator for a diagnostic procedure in a hospital outpatient setting is reimbursed by Medicare at a higher rate if that technetium dose is produced from a generator containing at least 95% LEU Moly. In January 2013, we began to offer a TechneLite generator which contains at least 95% LEU Moly and which satisfies the requirements for reimbursement under this incentive program. Although demand for LEU generators appears to be growing, we do not know when, or if, this incremental reimbursement for LEU Moly generators will result in a material increase in our generator sales.consistent with any recurring fair value estimate of such CVRs.
Research and Development Expenses
To remain a leader in the marketplace, we have historically made substantial investments in new product development. Asdevelopment, including, among other things, our flurpiridaz F 18 clinical development program, the expenses of which are now being borne by GE Healthcare. The Progenics Acquisition resulted in additional and substantial clinical development expense. The PYLARIFY NDA filed with the FDA on September 29, 2020, was approved by the FDA in May 2021. For 1095, the ARROW Phase 2 study in mCRPC patients had been paused to minimize risk to subjects and healthcare providers during the pandemic, and new enrollment in that study restarted in October 2020. In the fourth quarter of 2021, we completed an interim analysis of the ARROW Phase 2 study. The Independent Data Monitoring Committee recommended the study continue without modifications.
We also are planning additional clinical development work for AZEDRA in two new potential therapeutic indications – neuroblastoma and gastroenteropancreatic neuroendocrine tumors – and LMI 1195 as a result, the positive contributions of those internally funded research and development programs have been a key factor in our historical results and success. On April 25, 2017, we announced entering into a definitive, exclusive Collaboration and License Agreement with GE Healthcarediagnostic agent for the continued Phase III developmentmanagement of neuroblastoma. In addition, the Company has developed aPROMISE, our artificial intelligence-based, deep learning-enabled, medical device software, which we also refer to as PYLARIFY AI, and worldwide commercializationwhich is further described below under the heading “Additional Initiatives”. Our investments in these additional clinical activities will increase our operating expenses and impact our results of flurpiridaz F 18. In the future, we may also seek to engage strategic partners for our 18F LMI 1195operations and LMI 1174 programs, or we may choose to partially or fully fund one or more development programs ourselves. See Part I, Item 1. “Business—Researchcash flow, and Development—Proposed GE Healthcare Transaction” and Part I, Item 1A. “Risk Factors—We may not be able to further develop or commercialize our agents in development without successful strategic partners” of our Annual Report on Form 10-K for the year ended December 31, 2016.
Hurricane Maria in Puerto Rico
In September 2017, Hurricane Maria devastated Puerto Rico, interrupting power and telecommunications services for most of the island and limiting ground and air transportation. We operate a radiopharmacy in San Juan, Puerto Rico; the building that houses our radiopharmacy sustained minimal external physical damage as a result of the hurricane. From and after September 20, 2017, the number of diagnostic imaging procedures performed on the island has severely declined. While we currently believe that the number of diagnostic imaging procedures performed in Puerto Rico will slowly return to prior levels, we can give no assurances as to whether any of that,these clinical development candidates will be approved.
Additional Initiatives
In addition to integrating the new assets and failureprograms resulting from the Progenics Acquisition, we continue to seek ways to further expand our portfolio of products and product candidates and how best to optimize the value of our radiopharmacycurrent assets, evaluating a number of different opportunities to returncollaborate with others or to such prior levels could haveacquire or in-license additional products, product candidates, businesses and technologies to drive our future growth. Consistent with the Progenics Acquisition, we are particularly interested in expanding our presence in oncology, in both radiotherapeutics and diagnostics.
•In May 2019, we commenced an initiative to build out our Pharma Services capabilities, which resides in our strategic partnerships and other revenue product category, by entering into a negative effectstrategic collaboration and license agreement with NanoMab, a privately-held biopharmaceutical company focusing on the revenuedevelopment of next generation radiopharmaceuticals for cancer precision medicine. We believe this collaboration will provide the first broadly-available
30
Table of Contents
PD-L1 imaging biomarker research tool to pharmaceutical companies and cash flowacademic centers conducting clinical trials on immuno-oncology treatments, including combination therapies.
•In March 2021, we acquired from Ratio Therapeutics LLC (“Ratio”) (previously Noria Therapeutics, Inc.) exclusive, worldwide rights to NTI-1309, an innovative imaging biomarker that targets fibroblast activation protein (“FAP”), an emerging target with broad potential imaging applicability and use in oncology. Under the terms of this agreement, Ratio will drive the early clinical development of NTI-1309. We are integrating NTI-1309 into our portfolio of imaging biomarkers as part of our business. See Part II, Item 1A. “Risk Factors—Pharma Services offering. Upon further clinical development, we will assess options to bring NTI-1309 to market as a diagnostic or potentially a therapeutic agent.
•We have also expanded our Pharma Services offering to include piflufolastat F 18 for pharmaceutical companies developing PSMA-targeted therapies and have entered into clinical supply agreements with each of Regeneron, Bayer and POINT BioPharma for use of piflufolastat F 18 in prostate cancer drug development programs. In September 2021, we entered into a development and commercialization collaboration with RefleXion Medical, Inc. to evaluate the U.S.use of piflufolastat F 18 to enable real-time therapeutic guidance of biology-guided radiotherapy in prostate cancer using the RefleXion X1TM platform.
•Our subsidiary, EXINI Diagnostics AB (“EXINI”), we are heavily dependent on a few large customershas developed PYLARIFY AI, which is designed to allow healthcare professionals and group purchasing organization arrangementsresearchers to generate a majorityperform quantitative assessments of our revenues for our medical imaging products. OutsidePSMA PET/CT in oncology. Clinicians will have the option to utilize PYLARIFY AI with PYLARIFY to increase the efficiency and reproducibility of the U.S.,PSMA PET/CT assessments. Earlier this year, we rely primarily on distributors to generate a substantial portion of our revenue.”
Segments
We report our results of operations in two operating segments: U.S. and International. We generate a greater proportion of our revenues and net incomeannounced that EXINI was granted 510(k) clearance by the FDA for PYLARIFY AI in the U.S. segment, which consistsand that EXINI received CE Mark clearance for PYLARIFY AI in Europe.
We can give no assurance as to when or if any of all regionsthese Pharma Services collaborations and other new initiatives will be successful or accretive to earnings.
In addition, as described above, we continue to expand our microbubble franchise. See “Anticipated Continued Growth of the U.S. with the exceptionDEFINITY and Expansion of Puerto Rico.Our Ultrasound Microbubble Franchise–New Clinical Applications” for further details.

Executive Overview
Our results for the three and nine months ended September 30, 2017 as compared to the corresponding periods in 2016 reflect the following:
increased revenues and segment penetration for DEFINITY in the suboptimal echocardiogram segment as a result of our continued focused sales efforts;
increased revenues for TechneLite, mainly the result of higher contracted volumes from certain customers;
increased revenues of $5.0 million from GE Healthcare for the continued Phase III development and worldwide commercialization of flurpiridaz F 18;
lower international revenues and cost of goods sold as a result of the sales of our Canadian and Australian radiopharmacies in 2016;
increased depreciation expense as a result of the scheduled decommissioning of certain long-lived assets;
general and administrative expense of $1.7 million incurred in connection with the refinancing of our debt as well as a related $2.2 million loss on the extinguishment of debt; and
decreased interest expense due to the refinancing of long-term debt and a lower principal balance on our long-term debt.
Results of Operations
The following is a summary of our consolidated results of operations:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)20212020Change $Change %20212020Change $Change %
Revenues$102,073 $88,544 $13,529 15.3 %$295,646 $245,258 $50,388 20.5 %
Cost of goods sold59,404 52,284 7,120 13.6 %165,859 145,148 20,711 14.3 %
Gross profit42,669 36,260 6,409 17.7 %129,787 100,110 29,677 29.6 %
Operating expenses
Sales and marketing17,195 11,609 5,586 48.1 %48,999 28,044 20,955 74.7 %
General and administrative28,550 18,217 10,333 56.7 %87,865 55,586 32,279 58.1 %
Research and development11,252 11,684 (432)(3.7)%33,673 20,150 13,523 67.1 %
Total operating expenses56,997 41,510 15,487 37.3 %170,537 103,780 66,757 64.3 %
Gain on sale of assets— — — N/A15,263 — 15,263 N/A
Operating loss(14,328)(5,250)(9,078)172.9 %(25,487)(3,670)(21,817)594.5 %
Interest expense1,569 2,808 (1,239)(44.1)%6,224 6,668 (444)(6.7)%
Gain on extinguishment of debt— — — N/A(889)— (889)N/A
Other loss (income)3,940 (596)4,536 (761.1)%3,209 (1,702)4,911 (288.5)%
 Loss before income taxes(19,837)(7,462)(12,375)165.8 %(34,031)(8,636)(25,395)294.1 %
Income tax (benefit) expense(6,422)(1,076)(5,346)496.8 %(2,967)1,425 (4,392)(308.2)%
Net loss$(13,415)$(6,386)$(7,029)110.1 %$(31,064)$(10,061)$(21,003)208.8 %

31
 Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands)2017 2016 2017 2016
Revenues$79,941
 $73,063
 $250,137
 $227,503
Cost of goods sold41,414
 39,382
 125,901
 124,370
Gross profit38,527
 33,681
 124,236
 103,133
Operating expenses       
Sales and marketing10,075
 8,706
 31,892
 27,856
General and administrative12,076
 10,091
 35,549
 28,842
Research and development3,554
 2,849
 14,149
 8,493
Total operating expenses25,705
 21,646
 81,590
 65,191
Gain on sales of assets—
 (560) —
 (6,505)
Operating income12,822
 12,595
 42,646
 44,447
Interest expense4,442
 6,792
 14,147
 20,799
Debt retirement costs—
 1,415
 —
 1,415
Loss on extinguishment of debt—
 —
 2,161
 —
Other (income) expense(908) 148
 (2,037) (317)
Income before income taxes9,288
 4,240
 28,375
 22,550
Provision for income taxes762
 20
 2,116
 657
Net income$8,526
 $4,220
 $26,259
 $21,893

Table of Contents
Comparison of the Periods Ended September 30, 20172021 and 20162020
Revenues
SegmentWe classify our revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of PYLARIFY and AZEDRA. Strategic partnerships and other includes partnerships related to other products of the Company, such as RELISTOR, that improve patient outcomes and care.
Revenues are summarized by product category on a net basis as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021
2020(1)
Change $Change %20212020Change $Change %
   DEFINITY$57,636 $50,359 $7,277 14.5 %$173,448 $139,989 $33,459 23.9 %
   TechneLite22,680 21,113 1,567 7.4 %69,252 62,560 6,692 10.7 %
   Other precision diagnostics7,563 8,585 (1,022)(11.9)%21,289 28,782 (7,493)(26.0)%
Total precision diagnostics87,879 80,057 7,822 9.8 %263,989 231,331 32,658 14.1 %
Radiopharmaceutical oncology8,890 3,323 5,567 167.5 %13,203 7,474 5,729 76.7 %
Strategic partnerships and other5,304 5,164 140 2.7 %18,454 6,453 12,001 186.0 %
   Total revenues$102,073 $88,544 $13,529 15.3 %$295,646 $245,258 $50,388 20.5 %

  Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands) 2017 2016 
Change
$
 
Change
%
 2017 2016 
Change
$
 
Change
%
U.S.                
DEFINITY $36,901
 $32,007
 $4,894
 15.3 % $113,035
 $95,497
 $17,538
 18.4 %
TechneLite 22,621
 20,906
 1,715
 8.2 % 69,150
 64,282
 4,868
 7.6 %
Xenon 7,726
 6,675
 1,051
 15.7 % 23,709
 21,620
 2,089
 9.7 %
Other 2,331
 3,033
 (702) (23.1)% 12,812
 11,288
 1,524
 13.5 %
Total U.S. revenues 69,579
 62,621
 6,958
 11.1 % 218,706
 192,687
 26,019
 13.5 %
International                
DEFINITY 828
 597
 231
 38.7 % 2,534
 2,002
 532
 26.6 %
TechneLite 3,735
 3,627
 108
 3.0 % 10,750
 10,339
 411
 4.0 %
Xenon —
 2
 (2) (100.0)% 4
 5
 (1) (20.0)%
Other 5,799
 6,216
 (417) (6.7)% 18,143
 22,470
 (4,327) (19.3)%
Total International revenues 10,362
 10,442
 (80) (0.8)% 31,431
 34,816
 (3,385) (9.7)%
Total revenues $79,941
 $73,063
 $6,878
 9.4 % $250,137
 $227,503
 $22,634
 9.9 %
(1)The Company reclassified rebates and allowances of $5.5 million and $13.8 million within each product category, which included $5.1 million and $12.6 million for DEFINITY, $0.3 million and $0.9 million for TechneLite and $0.1 million and $0.2 million for other precision diagnostics, for the three and nine months ended September 30, 2020, respectively.
The increase in the U.S. segment revenues for the three months ended September 30, 2017,2021, as compared to the prior year period, is primarily due to a $4.9 million increasedriven by increases in DEFINITY revenuesand TechneLite volume period over period as a result of higher unit volumes, a $1.7 million increasethe COVID-19 pandemic in TechneLite revenues primarily as a resultthe prior year and the commercial launch of increased unit volumes and a $1.1 million increasePYLARIFY, offset, in Xenon revenues as a resultpart, by the divestiture of higher unit volumes. Offsetting these increases was a $0.7 million decrease due to rebate and allowance provisions.our Puerto Rico business during the first quarter of 2021.
The increase in the U.S. segment revenues for the nine months ended September 30, 2017,2021, as compared to the prior year period, is primarily due to a $17.5 million increasedriven by increases in DEFINITY revenuesand TechneLite volume period over period as a result of higher unit volumes, a $4.9 million increasethe COVID-19 pandemic in TechneLite revenues primarily as a result of increased unit volumes and a $2.1 million increase in Xenon as a result of higher unit volumes. In addition, there was an increase of $5.0 million in other revenue associated with the up-front license fee recognized related to the License Agreement with GE Healthcare for the continued Phase III development and worldwide commercialization of flurpiridaz F 18. Offsetting these increases was a $1.9 million decrease due to rebate and allowance provisions, as well as a $1.6 million decrease in Ablavar revenues as the product is no longer sold.
The International segment revenues for the three months ended September 30, 2017, were consistent compared to the prior year, period. The decrease in the International segment revenues for the nine months ended September 30, 2017, as compared to the prior year period is primarily the resultaddition of the saleProgenics product portfolio, including the commercial launch of PYLARIFY. This increase is partially offset by continued COVID-19 related reduced volumes in Xenon and the Australian radiopharmacydivestiture of our Puerto Rico business during 2016.the first quarter of fiscal year 2021.
Rebates and Allowances
Estimates for rebates and allowances represent our estimated obligations under contractual arrangements with third parties. Rebate accruals and allowances are recorded in the same period the related revenue is recognized, resulting in a reduction to revenue and the establishment of a liability which is included in accrued expenses. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and growth, Medicaid rebate programs for our products, administrative fees of group purchasing organizations royalties and certain distributor related commissions. The calculation of the accrual for these rebates and allowances is based on an estimate of the third-party’s buying patterns and the resulting applicable contractual rebate or commission rate(s) to be earned over a contractual period.

An analysis of the amount of, and change in, reserves is summarized as follows:
(in thousands)Rebates and
Allowances
Balance, January 1, 2021$9,350 
Provision related to current period revenues19,459 
Adjustments relating to prior period revenues(33)
Payments or credits made during the period(19,361)
Balance, September 30, 2021$9,415 

32
(in thousands)Rebates and
Allowances
Balance, as of January 1, 2017$2,297
Current provisions relating to revenues in current year6,864
Adjustments relating to prior years’ estimate(154)
Payments/credits relating to revenues in current year(4,658)
Payments/credits relating to revenues in prior years(1,474)
Balance, as of September 30, 2017$2,875
Costs
Table of Goods Sold
Cost of goods sold consists of manufacturing, distribution, intangible asset amortization, write-offs of excess and obsolete inventory and other costs related to our commercial products.
Cost of goods sold is summarized by segment as follows:
Contents
  Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands) 2017 2016 Change
$		 Change
%		 2017 2016 Change
$		 Change
%
U.S. $32,759
 $31,133
 $1,626
 5.2% $100,225
 $96,791
 $3,434
 3.5 %
International 8,655
 8,249
 406
 4.9% 25,676
 27,579
 (1,903) (6.9)%
Total cost of goods sold $41,414
 $39,382
 $2,032
 5.2% $125,901
 $124,370
 $1,531
 1.2 %
The increases in the U.S. segment cost of goods sold for the three and nine months ended September 30, 2017 as compared to the prior year periods are primarily due to costs associated with the increase in sales volume as noted above. We also incurred, increases in technology transfer expense, partially offset by lower amortization expense as a result of a fully amortized intangible asset.Gross Profit
The increase in the International segment cost of goods soldgross profit for the three months ended September 30, 20172021, as compared to the prior year period is primarily due to higher manufacturing costs for certain products due to higher salesDEFINITY volume increases and PYLARIFY post commercial launch volume increases, which are partially offset by lower manufacturing costs as a resultamortization expense of assets acquired in the sale of our Australian radiopharmacy business.Progenics Acquisition.
The decreaseincrease in the International segment cost of goods soldgross profit for the nine months ended September 30, 20172021, as compared to the prior year period is primarily due to lower manufacturing costs as a resultDEFINITY volume increases and an asset impairment loss of the sale of our Australian radiopharmacy business, partially offset by higher manufacturing costs for certain$7.3 million on other nuclear products due to higher sales volume and higher material costs for certain products.
Gross Profit
Gross profit is summarized by segment as follows:
  Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands) 2017 2016 
Change
$
 
Change
%
 2017 2016 
Change
$
 
Change
%
U.S. $36,820
 $31,488
 $5,332
 16.9 % $118,481
 $95,896
 $22,585
 23.6 %
International 1,707
 2,193
 (486) (22.2)% 5,755
 7,237
 (1,482) (20.5)%
Total gross profit $38,527
 $33,681
 $4,846
 14.4 % $124,236
 $103,133
 $21,103
 20.5 %
The increasethat occurred in the U.S. segment gross profit for the three months ended September 30, 2017 over the prior year period is primarily due to higher DEFINITY unit volumes and higher Xenon unit volumes.

Theyear. This increase was offset, in the U.S. segment gross profit for the nine months ended September 30, 2017 over the prior year period is primarily due to higher DEFINITY unit volumes, higherpart, by lower Xenon unit volumes and the recognitionincreased radioisotope transportation costs, both due to COVID-19, as well as amortization expense of $5.0 million in other revenue associated with the License Agreement with GE Healthcare for the continued Phase III development and worldwide commercialization of flurpiridaz F 18 without any associated cost of goods sold.
The decreasesassets acquired in the International segment gross profit for the three and nine months ended September 30, 2017 over the prior year periods are primarily due to higher manufacturing and material costs for certain products.Progenics Acquisition.
Sales and Marketing
Sales and marketing expenses consist primarily of salaries and other related costs for personnel in field sales, marketing business development and customer service functions. Other costs in sales and marketing expenses include the development and printing of advertising and promotional material, professional services, market research and sales meetings.
Sales and marketing expense is summarized by segment as follows:
 Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands)2017 2016 
Change
$
 
Change
%
 2017 2016 
Change
$
 
Change
%
U.S.$9,480
 $8,021
 $1,459
 18.2 % $29,854
 $24,902
 $4,952
 19.9 %
International595
 685
 (90) (13.1)% 2,038
 2,954
 (916) (31.0)%
Total sales and marketing$10,075
 $8,706
 $1,369
 15.7 % $31,892
 $27,856
 $4,036
 14.5 %
The increases in the U.S. segment salesexpenses increased $5.6 million and marketing expenses$21.0 million for the three and nine months ended September 30, 2017 over2021, respectively, as compared to the prior year periods areperiod. This was primarily due to employee-related expenses, market research and promotional program expenses.
The decreases indriven by the International segmentintegration of the Progenics sales and marketing expensesorganization, preparation activities for the threelaunch of PYLARIFY and nine months ended September 30, 2017 overincreased employee-related costs, as well as the reduced level of marketing promotional programs during the prior year periods are primarily due to lower headcount.the impact of the COVID-19 pandemic.
General and Administrative
General and administrative expenses consist of salaries and other related costs for personnel in executive, finance, legal, information technology and human resource functions. Other costs included in general and administrative expenses are professional fees for information technology services, external legal fees, consulting and accounting services as well as bad debt expense, certain facility and insurance costs, including director and officer liability insurance.
General and administrative expense is summarized by segment as follows:
 Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands)2017 2016 
Change
$
 
Change
%
 2017 2016 
Change
$
 
Change
%
U.S.$11,901
 $9,693
 $2,208
 22.8 % $35,055
 $27,629
 $7,426
 26.9 %
International175
 398
 (223) (56.0)% 494
 1,213
 (719) (59.3)%
Total general and administrative$12,076
 $10,091
 $1,985
 19.7 % $35,549
 $28,842
 $6,707
 23.3 %
The increase in the U.S. segment general and administrative expenses increased $10.3 million for the three months ended September 30, 2017 over2021 compared to the prior period. This was primarily driven by the $9.5 million sublease impairment charge and $2.6 million fair value adjustment to the contingent asset and liabilities in the third quarter of 2021 (an increase of $1.8 million from the prior year period are primarily dueperiod) (refer to higher employee-related expenses and campus consolidation costs.Note 4, “Fair Value of Financial Instruments”, for further details on contingent consideration liabilities, including CVRs), offset by acquisition-related costs associated with the Progenics Acquisition in the prior year.
The increase in U.S. segment generalGeneral and administrative expenses increased $32.3 million for the nine months ended September 30, 2017 over2021 compared to the prior year period areperiod. This was primarily duedriven by the $28.5 million fair value adjustment to $1.7the contingent asset and liabilities (an increase of $27.7 million of debt refinancing costs, higher employee-related expenses and campus consolidation costs.
The decreases in the International segment general and administrative expenses for the three and nine months ended September 30, 2017 overfrom the prior year periods are primarily due to lower employeeperiod), $9.5 million sublease impairment charge and higher headcount related costs following the Progenics Acquisition, offset by acquisition-related costs associated with the Progenics Acquisition in the prior year and related expenses.synergy capture in the current year.

Research and Development
Research and development expenses relate primarily to the development of new products to add to our portfolio and costs related to itsour medical affairs, medical information and regulatory functions. We do not allocate research and development expenses incurred in the United States to our International segment.
Research and development expense is summarized by segment as follows:
 Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands)2017 2016 
Change
$
 
Change
%
 2017 2016 
Change
$
 
Change
%
U.S.$3,196
 $2,685
 $511
 19.0% $13,265
 $7,985
 $5,280
 66.1%
International358
 164
 194
 118.3% 884
 508
 376
 74.0%
Total research and development$3,554
 $2,849
 $705
 24.7% $14,149
 $8,493
 $5,656
 66.6%
The increase in the U.S. segment research and development expenses decreased $0.4 million for the three months ended September 30, 2017 over2021 as compared to the prior year period isperiod. This was primarily duedriven by the filing fee related to an increase inthe PYLARIFY New Drug Application and preparation activities for the launch of PYLARIFY during the prior year period; offset by phasing of the ARROW Phase 2 study of 1095 and higher employee-related expenses.overall headcount related costs.
The increase in the U.S. segment researchResearch and development expenses increased $13.5 million for the nine months ended September 30, 2017 over2021 as compared to the prior year period isperiod. This was primarily due to an increase in depreciation expense and other charges as a resultdriven by the integration of the scheduled decommissioning of certain long-lived assets associated withProgenics research and development operations as well asorganization now supporting our pipeline, which includes 1095, preparation activities for the launch of PYLARIFY and higher employee-related expenses, partially offset by lower pharmacovigilance expensescosts due to the transition to a new vendor inimpact of the prior year.
The increases in International segment research and development expenses for the three and nine months ended September 30, 2017 overCOVID-19 pandemic during the prior year periods were drivenperiod; offset by a European Phase IV study for one of our products.the filing fee related to the PYLARIFY New Drug Application during the prior year period.
Gain on SalesSale of Assets
Effective January 7, 2016, our Canadian subsidiary entered into an asset purchase agreement, pursuant to which it would sell substantially all of the assets of our Canadian radiopharmacies and Gludef manufacturing and distribution business to one of our existing Canadian radiopharmacy customers. The purchase price for the asset sale was $9.0 million in cash and also included a working capital adjustment of $0.5 million, resulting in a pre-tax gain of $5.9 million recorded within operating income during the nine months ended September 30, 2016.
Effective August 11, 2016, we entered into a share purchase agreement, pursuant to which weWe sold 100% of the stock of our AustralianPuerto Rico radiopharmacy subsidiary to one of our existing radiopharmacy customers. This sale included the radiopharmacy business as well as all the direct/bulk business. The sale price for the share sale was AUD$2.0 million (approximately $1.5 million U.S. Dollars) in cash and also included a working capital receivable adjustment of approximately AUD$2.0 million (approximately $1.5 million U.S. Dollars), resulting in a pre-tax book gain of $0.6$15.3 million which was recorded within operating income for the nine months ended September 30, 2016.2021.
33
Table of Contents
Interest Expense
Interest expense decreased by approximately $2.4 million and $6.7$0.4 million for the three and nine months ended September 30, 2017, respectively,2021 as compared to the prior year periods,period due to the March 2017 refinancing oflower interest rates on our long-term debt and reductions in the principal balance of our long-term debt related to the 2017 refinancing and the voluntary principal prepayments we made during September and November 2016.debt.
Loss
Gain on Extinguishment of Debt
For the nine months ended September 30, 2017,2021, we incurredrealized a $2.2$0.9 million lossgain on extinguishment of debt in connection withrelated to the refinancingvoluntary repayment of our existing indebtedness with the new term loan and revolving credit facilities, see Note 8, “Financing Arrangements” to our condensed consolidated financial statements.outstanding principal on the Royalty-Backed Loan on March 31, 2021.

Provision for Income TaxesTax (Benefit) Expense
Provision forThe income taxestax benefit recorded for the periods presented is as follows:three months ended September 30, 2021 was primarily due to the tax benefit of a release of uncertain tax position liability, and a pre-tax loss reported during the quarter partially offset by the accrual of interest associated with uncertain tax positions.
 Three Months Ended
September 30,		 Nine Months Ended
September 30,
(in thousands)2017 2016 
Change
$
 
Change
%
 2017 2016 
Change
$
 
Change
%
Provision for income taxes$762
 $20
 $742
 >1,000% $2,116
 $657
 $1,459
 222.1%
Our provisionThe income tax benefit recorded for income taxes resultsthe nine months ended September 30, 2021 was primarily fromdue to the tax benefit of released of uncertain tax position liabilities and the pre-tax loss reported during the period, partially offset by the accrual of interest and penalties associated with uncertain tax positions offset by reversalsand the impact of those positions as statutes lapse or such positions are settled duringpermanent item adjustments including the year, as well as taxes due in certain foreign jurisdictions where we generate taxable income. The $0.7 million and $1.5 million increases in the tax provision for the three and nine months ended September 30, 2017, as compared to the same periods in 2016 primarily reflect a reduced amountaccrual of statute lapses and consequent liability releases in the current period, when compared with the prior year period.contingent consideration liabilities.
We regularly assess our ability to realize our deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether our deferred tax assets are more likely than notmore-likely-than-not realizable, we evaluatedevaluate all available positive and negative evidence, and weighedweigh the objective evidence and expected impact. Evidence considered included our history of net operating losses, which resulted in our recording ofWe continue to record a full valuation allowance against certain of our domesticforeign net deferred tax assets beginningand a small component of our domestic deferred tax assets.
Our effective tax rate for each reporting period is presented as follows:
Nine Months Ended
September 30,
20212020
Effective tax rate8.7%(16.5)%
Our effective tax rate in 2011,fiscal 2021 differs from the U.S. statutory rate of 21% principally due to releases of uncertain tax position liabilities and the impact of non-deductible contingency reserve expense.
The decrease in each year thereafter. We were profitable on a cumulative basisthe effective income tax rate for the three-year period ended September 30, 2017, but substantially all of that profitability was achieved during 2016 and the nine months ended September 30, 2017.
We continue2021 is primarily due to evaluate other negative evidence, including customer concentration and contractual risk, the riskreduction in tax benefit resulting from the accrual of Moly supply availability and cost, DEFINITY supplier risk, and certain product development risks, all of which provide for uncertainties around our future level of profitability. Based on our review of all available evidence, we determined that we have not yet attained a sustained level of profitability sufficient to outweigh the objectively verifiable negative evidence, and have recorded a full valuation allowance against our domestic net deferred tax assets at September 30, 2017. We will continue to assess the level of the valuation allowance required. If a sufficient weight of positive evidence exists in future periods to support a release of some or all of the valuation allowance recorded against domestic deferred tax assets, such a release would likely have a material impact on our results of operations in that future period.
Our effective tax rate for the periods presented are as follows:non-deductible contingency reserve expense.
34
  Nine Months Ended September 30,
  2017 2016
Effective tax rate 7.5% 2.9%

Table of Contents
Liquidity and Capital Resources
Cash Flows
The following table provides information regarding our cash flows:
Nine Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2017 2016(in thousands)20212020
Net cash provided by operating activities$41,691
 $36,861
Net cash provided by operating activities$40,027 $15,827 
Net cash (used in) provided by investing activities$(10,355) $5,639
Net cash provided by (used in) investing activitiesNet cash provided by (used in) investing activities$8,227 $(1,127)
Net cash used in financing activities$(14,600) $(17,958)Net cash used in financing activities$(37,232)$(17,488)
Net Cash Provided by Operating Activities
CashNet cash provided by operating activities of $41.7$40.0 million in the nine months ended September 30, 20172021 was driven primarily by net income of $26.3 million plus $15.0 million of depreciation, amortization and accretion expense $3.8of $30.1 million, a change in fair value of contingent assets and liabilities of $28.5 million (refer to Note 4, “Fair Value of Financial Instruments”, for further details on contingent consideration liabilities, including CVRs), stock-based compensation expense of $11.8 million, impairment of long-lived assets of $9.5 million and a $2.2net increase of $2.4 million loss on debt extinguishment.related to movements in our working capital accounts during the period. The overall increases in cash from our working capital accounts were primarily driven by an increase in sales collections, the timing of payments to large vendors, and an increase in fees related to PYLARIFY sales. These net sources of cash were offset by a net loss of $31.1 million and a gain on sale of assets of $15.3 million.
Net cash provided by operating activities of $15.8 million in the nine months ended September 30, 2020 was driven primarily by $16.3 million of depreciation, amortization and accretion expense, stock-based compensation expense of $10.5 million, and impairment of long-lived assets of $7.3 million. These net sources of cash were offset by a net loss of $10.1 million and a net decrease of $8.9$11.7 million related to movements in our working capital accounts during the period. The overall decreases in cash from our working capital accounts were primarily driven by higher accounts receivablethe payment of prior year annual bonuses as well as change in inventory related to increases in revenues to certain major customersthe COVID-19 impact on products and the timing of inventory purchases duringbatch processes and accruals related to general and administrative expenses in connection with the period.acquisition of Progenics.
Net Cash Provided by (Used in) Investing Activities
Net cash provided by operatinginvesting activities of $36.9 million induring the nine months ended September 30, 20162021 was driven primarily due to cash proceeds of $15.8 million received from the sale of our Puerto Rico subsidiary, which was offset by net income of $21.9 million plus $12.7$7.6 million of depreciation, amortization and accretion expense, $1.9 million of stock-based compensation expense and $1.4 million of debt retirement costs. These net sources of cash were offset by the gain on sales of assets of $6.5 million. In addition, we had a $3.6 million net increase related to movements in our working capital during the period. The overall increases in cash from our working capital accounts were primarily driven by the timing of payment runs, timing of payroll and accrued bonuses, and improved collections, which were offset by an increase in inventory due to the timing of production and receipt of inventory and an increase in prepaid expenses due to insurance renewals.
Net Cash (Used in) Provided by Investing Activitiesexpenditures.
Net cash used in investing activities during the nine months ended September 30, 20172020 reflected $11.6$10.0 million in lending on a note receivable to Progenics prior to the acquisition and $8.7 million in capital expenditures offset by $17.6 million of acquired cash related to the cash proceeds of $1.2 million received from the sale of assets from our Australian radiopharmacy business during the third quarter of 2016.
Net cash provided by investing activities during the nine months ended September 30, 2016 was primarily due to cash proceeds of $10.5 million received from the sale of assets from our Canadian and Australian radiopharmacy businesses, which was offset by $5.0 million in capital expenditures.non-cash Progenics Acquisition.
Net Cash Used in Financing Activities
Net cash used in financing activities during the nine months ended September 30, 20172021 is primarily attributable to the payments on long-term debt and other borrowings of $40.8 million related to the 2019 Term Facility and Royalty-Backed Loan, including a voluntary repayment of the outstanding principal on the Royalty-Backed Loan and payments for minimum statutory tax withholding related to net outflowshare settlement of $11.9equity awards of $1.9 million in connection with our refinancingoffset by proceeds of our previous $365.0$4.6 million seven-year term loan agreement with a new five-year $275.0 million term loan facility.from stock option exercises.
Net cash used in financing activities during the nine months ended September 30, 2016 was2020 is primarily usedattributable to repay $55.0the payments on long-term debt and other borrowings of $11.2 million ofrelated to the principal balance of our $365.0 million2019 Term Facility withand Royalty-Backed Loan, equity issuance costs related to the acquisition of Progenics of $3.8 million, and payments for minimum statutory tax withholding related to net proceedsshare settlement of $39.9 million, which were raised upon completionequity awards of a follow-on underwritten primary offering, and $15.1 million from cash on hand.$2.1 million.
External Sources of Liquidity
OnIn June 30, 2015, we completed our initial public offering, entered into a $365.0 million seven-year term facility (the “2015 Term Facility”) and amended and restated our revolving facility (the “2015 Revolving Facility”) that had a borrowing capacity of $50.0 million.
In September 2016, we completed a follow-on underwritten offering of 5,200,000 shares of common stock and utilized the net proceeds to us from this offering, combined with cash on hand, to prepay $55.0 million of the principal balance of our 2015 Term Facility. In November 2016, we completed a second follow-on underwritten offering that included 1,000,000 shares of common stock

offered by us and utilized the net proceeds to us from this offering, combined with cash on hand, to prepay $20.0 million of the principal balance of our 2015 Term Facility. As of December 31, 2016, the principal balance outstanding on our 2015 Term Facility was $284.5 million.
In March 2017,2019, we refinanced the 2015 Term Facility with a new five-yearour 2017 $275.0 million five-year term loan facility (the “2017with the 2019 Term Facility” and the loans thereunder, the “Term Loans”).Facility. In addition, we replaced our 2015 Revolving Facility$75.0 million revolving facility with a new $75.0 millionour five-year revolving credit facility (the “2017“2019 Revolving Facility” and, together with the 20172019 Term Facility, the “2017“2019 Facility”, the). The terms of whichthe 2019 Facility are set forth in the Credit Agreement). The 2017 Term Facility was issued netAgreement, dated as of a $0.7 million discount.June 27, 2019, by and among us, the lenders from time to time party thereto and Wells Fargo Bank, N.A., as administrative agent and collateral agent. We have the right to request an increase to the 20172019 Term Facility or request the establishment of one or more new incremental term loan facilities, in an aggregate principal amount of up to $75.0$100.0 million, plus additional amounts, in certain circumstances.
We used the net proceeds
35
Table of the 2017 Term Facility, together with approximately $15.3 million of cash on hand, to refinance in full the aggregate remaining principal amount of the loans outstanding under the 2015 Term Facility and pay related interest, transaction fees and expenses. No amounts were outstanding under the 2015 Revolving Facility at that time.Contents
The Term Loans under the 2017 Term Facility bear interest, with pricing based from time to time at our election at (i) LIBOR plus a spread of 4.50% or (ii) the Base Rate (as defined in the Credit Agreement) plus a spread of 3.50%. Interest is payable (i) with respect to LIBOR Term Loans, at the end of each Interest Period (as defined in the Credit Agreement) and (ii) with respect to Base Rate Term Loans, at the end of each quarter. At September 30, 2017, our interest rate under the 2017 Term Facility was 5.7%.
We are permitted to voluntarily prepayrepay the 2019 Term Loans, in whole or in part.part, without premium or penalty. The 20172019 Term Facility requires us to make mandatory prepayments of the outstanding 2019 Term Loans in certain circumstances. The 20172019 Term Facility amortizes at 1.00%5.0% per year through September 30, 2022 and 7.5% thereafter, until its June 30, 202227, 2024 maturity date.
Under the terms of the 20172019 Revolving Facility, the lenders thereunder agreed to extend credit to us from time to time until March 30, 2022 (the “Revolving Termination Date”)June 27, 2024 consisting of revolving loans (the “Revolving Loans” and, together with the Term Loans, the “Loans”) in an aggregate principal amount not to exceed $75.0$200.0 million (the “Revolving Commitment”) at any time outstanding. The 20172019 Revolving Facility includes a $20.0 million sub-facility for the issuance of lettersLetters of credit (the “Letters of Credit”).Credit. The 2019 Revolving Facility includes a $10.0 million sub-facility for Swingline Loans. The Letters of Credit, Swingline Loans and the borrowings under the 20172019 Revolving Facility are expected to be used for working capital and other general corporate purposes.
Please refer to our Form 10-K for fiscal year ended December 31, 2020 for further details on the 2019 Facility.
On June 19, 2020, we amended our 2019 Credit Agreement (the “Amendment”) as a result of the impact of the COVID-19 pandemic on our business and operations and the near-term higher level of indebtedness resulting from our decision not to immediately repay the Progenics debt secured by the RELISTOR royalties following the Progenics Acquisition.
The Revolving Loans under the 2017 Revolving Facility bear interest, with pricing based from timeAmendment provides for, among other things, modifications to time at our election at (i) LIBOR plus a spread of 3.50% or (ii) the Base Ratefinancial maintenance covenants. The covenant related to Total Net Leverage Ratio (as defined in the Amended Credit Agreement) plus a spreadwas waived from the date of 2.50%.the Amendment through December 31, 2020. The 2017 Revolving Facility also includes an unused line fee, which is set at 0.375% while our securedmaximum total net leverage ratio (as defined in the Credit Agreement) is greater than 3.00 to 1.00 and 0.25% when our secured leverage ratio is less than or equal to 3.00 to 1.00.
We are permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans and Letters of Credit exceeds the total Revolving Commitment, we must prepay the Revolving Loans in an amount equal to such excess. The 2017 Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The 2017 Facility requires us to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum consolidated leverageinterest coverage ratio permitted by the financial covenant is displayed in the table below:
2017 Facility Financial Covenant
2020 Amended Credit Agreement
PeriodTotal Net Leverage Ratio
Q3 2021 and Thereafter3.50 to 1.00
Period
Consolidated
LeverageInterest Coverage Ratio
Q3 2017 through Q1 2018Q2 2021 and thereafter5.00 to 1.00
Q2 2018 through Q1 20194.75 to 1.00
Thereafter4.503.00 to 1.00
The 2017 Facility contains usualAs of September 30, 2021, we were in compliance with all financial and customary restrictionsother covenants under the Amendment.
For the period beginning on the date of the Amendment and ending on the Adjustment Date (as defined in the Amended Credit Agreement) for the fiscal quarter ending March 31, 2021, loans under the Amended Credit Agreement bear interest at LIBOR plus 3.25% or the Base Rate plus 2.25%. On and after the Adjustment Date for the fiscal quarter ending on March 31, 2021, loans bear interest at LIBOR plus a spread that ranges from 1.50% to 3.00% or the Base Rate plus a spread that ranges from 0.50% to 2.00%, in each case based on our abilityTotal Net Leverage Ratio.
The commitment fee applicable to the Revolving Facility was 0.50% until the Adjustment Date for the fiscal quarter ending March 31, 2021. On and thatafter the Adjustment Date for the fiscal quarter ending on March 31, 2021, the commitment fee ranges from 0.15% to 0.40% based on our Total Net Leverage Ratio.
On June 19, 2020, as a result of our subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sellthe Progenics Acquisition, we assumed Progenics outstanding debt as of such date in the amount of $40.2 million. Progenics, through a wholly-owned subsidiary MNTX Royalties Sub LLC (“MNTX Royalties”), entered into a $50.0 million loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. (“HCRP”) on November 4, 2016. Under the terms of the Royalty-Backed Loan, the lenders had no recourse to Progenics or otherwise dispose of all or substantially allany of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or makeassets other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Upon an event of default, the administrative agent under the Credit Agreement will havethan the right to declarereceive royalty payments from the Loanscommercial sales of RELISTOR products owed under Progenics’ license agreement with Salix Pharmaceuticals, Inc., a wholly-owned subsidiary of Bausch. The RELISTOR royalty payments were used to repay the principal and other obligations outstanding immediately dueinterest on the loan. The Royalty-Backed Loan bore interest at a per annum rate of 9.5% and payable and all commitments immediately terminated or reduced.
The 2017 Facility is guaranteed by Holdings and Lantheus MI Real Estate, LLC (“LMI-RE”), and obligations underwas scheduled to mature on June 30, 2025. On June 22, 2020, HCRP waived the 2017 Facility are generally secured by first priority liens over substantially allautomatic acceleration of the assetsRoyalty-Backed Loan that otherwise would have been triggered by the consummation of each of LMI, Holdingsthe Progenics Acquisition and LMI-RE (subjectMNTX Royalties agreed not to customary exclusions set forthprepay the loan until after December 31, 2020.
On March 31, 2021, we voluntarily repaid in full the entire outstanding principal on the Royalty-Backed Loan in the transaction documents) owned asamount of March 30, 2017 or thereafter acquired.$30.9 million, which included a prepayment amount of $0.5 million, and terminated the agreement.
Our ability to fund our future capital needs will be affected by our ability to continue to generate cash from operations and may be affected by our ability to access the capital markets, money markets or other sources of funding, as well as the capacity and terms of our financing arrangements.
36
Table of Contents
We may from time to time repurchase or otherwise retire our debt and take other steps to reduce our debt or otherwise improve our balance sheet. These actions may include prepayments of our term loans or other retirements or refinancing of outstanding debt, privately negotiatednegotiated transactions or otherwise. The amount of debt that may be retired, if any, could be material and would be decided at the sole discretion of our Board of Directors and will depend on market conditions, our cash position and other considerations.
Funding Requirements
Our future capital requirements will depend on many factors, including:
Our ability to have product manufactured and released from JHS and other manufacturing sites in a timely manner in the future;
•The pricing environment and the level of product sales and the pricing environment of our currently marketed products, particularly DEFINITY and any additional products that we may market in the future;future, including decreased product sales resulting from the COVID-19 pandemic;
•Revenue mix shifts and associated volume and selling price changes that could result from contractual status changes with key customers and additional competition;
•The costs of the PYLARIFY commercial launch and our ability to successfully commercialize PYLARIFY;
•The costs of acquiring or in-licensing, developing, obtaining regulatory approval for, and commercializing, new products, businesses or technologies, together with the costs of pursuing opportunities that are not eventually consummated;
•Our investment in the further clinical development and commercialization of products and development candidates, including AZEDRA, PYLARIFY, 1095, LMI 1195, aBSI and PSMA AI;
•The costs of investing in our facilities, equipment and technology infrastructure;
•The costs and timing of establishing manufacturing and supply arrangements for commercial supplies of our products and raw materials and components;
•Our ability to have product manufactured and released from JHS and other manufacturing sites in a timely manner in the future, including our ability to negotiate a new manufacturing agreement with JHS for DEFINITY, or to begin and ramp up our manufacturing of DEFINITY at our in-house manufacturing facility in an amount sufficient to meet our supply needs;
•The costs of further commercialization of our existing products, particularly in international markets, including product marketing, sales and distribution and whether we obtain local partners to help share such commercialization costs;
The costs of investing in our facilities, equipment and technology infrastructure;
The costs and timing of establishing manufacturing and supply arrangements for commercial supplies of our products;
The extent to which we acquire or invest in (i) new products, businesses and technologies, or (ii) the further clinical development or commercialization of existing development candidates or products;
•The extent to which we choose to establish collaboration, co-promotion, distribution or other similar arrangements for our marketed products;
•The legal costs relating to maintaining, expanding and enforcing our intellectual property portfolio, pursuing insurance or other claims and defending against product liability, regulatory compliance or other claims; and
•The cost of interest on any additional borrowings which we may incur under our financing arrangements.
Until we successfullysuccessfully become dual sourced for our principal products, we are vulnerable to future supply shortages. Disruption in the financialour financial performance could also occur if we experience significant adverse changes in product or customer mix, broad economic downturns, adverse industry or company conditions or catastrophic external events, including pandemics such as COVID-19, natural disasters and political or military conflict. If we experience one or more of these events in the future, we may be required to further implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.
If our capital resources become insufficient to meet our future capital requirements, we would need to finance our cash needs through public or private equity offerings, debt financings, assets securitizations, debt financings, sale-leasebacks or other financing or strategic alternatives, to the extent such transactions are permissible under the covenants of the agreements governing our senior secured credit facilities.Credit Agreement. Additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all. If any of these transactions require an amendment or waiver under the covenants in the agreements governing our senior secured credit facilities,Credit Agreement, which could result in additional expenses associated with obtaining the amendment or waiver, we will seek to obtain such a waiver to remain in compliance with those covenants. However, we cannot be assured that such an amendment or waiver would be granted, or that additional capital will be available on acceptable terms, if at all.

At September 30, 2017,2021, our only current committed external source of funds is our borrowing availability under our 20172019 Revolving Facility. We had $68.1$91.5 million of cash and cash equivalents at September 30, 2017.2021. Our 20172019 Facility, as amended, contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the 20172019 Revolving Facility, as amended, may affect our ability to comply with the covenants in the 20172019 Facility, as amended, including the financial covenantcovenants restricting totalconsolidated net leverage.leverage and interest coverage. Accordingly, we may be limited in utilizing the full amount of our 20172019 Revolving Facility, as amended, as a source of liquidity.
37
Table of Contents
The CVRs we issued in the Progenics Acquisition entitle holders thereof to future cash payments of 40% of PYLARIFY net sales over (i) $100.0 million in 2022 and (ii) $150.0 million in 2023, which, if payable, we currently intend to fund from our then-available cash. In no event will our aggregate payments under the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% (which we estimate could be approximately $100.0 million) of the total consideration we pay in the Progenics Acquisition. Refer to Note 4, “Fair Value of Financial Instruments”, for further details on contingent consideration liabilities.
Based on our current operating plans, including our prudent expense management in response to the COVID-19 pandemic, we believe that our existing cash and cash equivalents, results of operations and availability under our 20172019 Revolving Facility, as amended, will be sufficient to continue to fund our liquidity requirements for the foreseeable future.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial positioncondition and results of operations isare based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that may affect theour reported amounts of assets and liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition and related allowances, inventory, impairments of long-lived assets including intangible assets, impairments of goodwill, income taxes including the valuation allowance for deferred tax assets.other financial information. Actual results may differ materially from these estimates under different assumptions and conditions. In addition, our reported financial condition and results of operations could vary due to a change in the application of a particular accounting standard.
There have been no materialother significant changes to our critical accounting policies or in the underlying accounting assumptions and estimates used in such policies in the nine months ended September 30, 2017.2021. For further information, refer to our summary of significant accounting policies and estimates in our Annual Report on Form 10-K filed for the year ended December 31, 2016.2020.
Off-Balance Sheet Arrangements
We are required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating our ability to fund the decommissioning of our North Billerica, Massachusetts production facility upon closure, though we do not intend to close the facility. We have provided this financial assurance in the form of a $28.2 million surety bond.
Since inception, we have not engaged in any other off-balance sheet arrangements, including structured finance, special purpose entities or variable interest entities.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
For quantitative and qualitative disclosures about market risk, see Part II, Item 7A,7A. “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2016.2020. Our exposures to market risk have not changed materially since December 31, 2016.2020.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (its(“CFO”), its principal executive officer and principal financial officer, respectively),respectively, has evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act as of September 30, 2017.Act. Based on that evaluation, the Company’s Chief Executive OfficerCEO and Chief Financial OfficerCFO concluded that the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were effective as of September 30, 2017.the period covered by this report.
Changes in Internal Controls Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarternine months ended September 30, 2017,2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are continually monitoring and assessing the pandemic status to determine any potential impact on the design and operating effectiveness of our internal controls over financial reporting.

38
Table of Contents
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
From timeInformation with respect to time, the Company is a party to variouscertain legal proceedings arisingis included in the ordinary course of business. In addition, the Company has in the past been,Note 19, “Commitments and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorablyContingencies”, to the Company. In addition, intellectual property disputes often have a riskcondensed consolidated financial statements contained in Part I, Item 1. Financial Statements of injunctive relief which, if imposed against the Company, could materiallythis Quarterly Report on Form 10-Q and adversely affect its financial condition or resultsis incorporated herein by reference.
39
Table of operations.Contents
As of September 30, 2017, the Company has no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.
Item 1A. Risk Factors
There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2016,2020, except as set forth below. For further information, referbelow:
The near-term growth of our business is substantially dependent on our ability to Part I, Item 1A. “Risk Factors”continue to grow the appropriate use of DEFINITY in our Annual Report on Form 10-K forsuboptimal echocardiograms in the year ended December 31, 2016.face of increased segment competition from other existing echocardiography agents and potential generic competitors.
The growth of our business is substantially dependent on increased market penetration forour ability to continue to grow the appropriate use of DEFINITY in suboptimal echocardiograms.
The growth of our business is substantially dependent on increased market penetration for the appropriate use of DEFINITY in suboptimal echocardiograms. Of the total number of echocardiograms performed each year in the U.S., over 31.8 million in 2016, based on medical literature, a third-party source estimates that 20%, or There were approximately 6.431.5 million echocardiograms in 2016,2020 according to a third-party source. Assuming 20% of echocardiograms produce suboptimal images, as stated in the clinical literature, we estimate that approximately 6.3 million echocardiograms in 2020 produced suboptimal images. We estimate that DEFINITY had an approximatelyheld over 80% share of the U.S. market for contrastultrasound enhancing agents in echocardiography procedures as of December 2016. 31, 2020. DEFINITY currently competes with Optison, a GE Healthcare product, Lumason, a Bracco Diagnostics Inc. (“Bracco”) product (known as SonoVue outside the U.S.), as well as echocardiography without ultrasound enhancing agents and other non-echocardiography agents.
We launched DEFINITY in 2001, and we continue to actively pursue additional patents in connection with DEFINITY and DEFINITY RT, both in the U.S., its and internationally. In the U.S. for DEFINITY we now own a total of four Orange Book-listed method of use patents, one of which expires in 2035 and three of which expire in 2037, as well as additional manufacturing patents that are not Orange Book-listed expiring in 2021, 2023 and 2037. In the U.S. for DEFINITY RT, we own a total of five Orange Book-listed patents, including a composition of matter patent will expirewhich expires in 2019, its manufacturing patent will expire in 2021, and a new method2035. Outside of use patent will expire in 2037. In numerous foreign jurisdictions, patent protection or regulatory exclusivity will currently expire in 2019. We have an active next generation development program for this agent, including pursuing additional indications, newthe U.S., while our original DEFINITY patent protection and new formulations,regulatory exclusivity have generally expired, we are currently prosecuting additional DEFINITY and DEFINITY RT patents to obtain similar patent protection as in the U.S. The Orange Book-listed patents include a patent on the use of VIALMIX RFID, which expires in 2037; additional VIALMIX RFID patent applications have been submitted in major markets throughout the world.
Because our Orange Book-listed composition of matter patent expired in June 2019, we may face generic DEFINITY challengers in the near to intermediate term. Under the Hatch-Waxman Act, the FDA can approve ANDAs for generic versions of drugs before the expiration of an Orange Book-listed patent covering the innovator product if the ANDA applicant demonstrates, among other things, that (i) its generic candidate is the same as the innovator product by establishing bioequivalence and providing relevant chemistry, manufacturing and product data, and (ii) the marketing of that generic candidate does not infringe an Orange Book-listed patent or that an Orange Book-listed patent is invalid. The ANDA applicant must also give Notice to the innovator, which would then enable the innovator to challenge the ANDA applicant in court within 45 days of receiving such Notice. If the innovator challenges the ANDA applicant in court in a timely manner, then FDA approval to commercialize the generic candidate will be stayed (that is, delayed) for up to 30 months while the dispute between the innovator and the ANDA applicant is resolved in court. The 30 month stay can be shortened if the patent infringement suit is resolved in the ANDA applicant’s favor before the 30 month stay expires, and this may involve a successful challenge of the patent’s validity in USPTO proceedings and appeals process.
As of the date of filing of this Quarterly Report on Form 10-Q, we have not received any such Notice from any ANDA applicant, but therewe can begive no assurance that this programwe will not receive a Notice in the future. If we were to receive any such Notice in the future, we would review the Notice, evaluate the strength of any potential patent infringement claims, and be prepared to challenge the ANDA applicant in a timely fashion, which would thereby trigger the stay of up to 30 months. We can give no assurance that we would have grounds to file a patent infringement suit, that we would obtain the full 30 month stay, that we would be successful on the merits asserting that a generic candidate infringes our Orange Book-listed patent, or that we would be successful defending the validity of our Orange Book-listed patent in court or in a USPTO adversarial proceeding. In addition, as discussed in our risk factor “Our business and industry are subject to complex and costly regulations. If government regulations are interpreted or enforced in a manner adverse to us or our business, we may be subject to enforcement actions, penalties, exclusion and other material limitations on our operations.”set forth below, if the FDA reclassified one or more of our imaging agents, such as DEFINITY, as a “device” rather than a “drug”, we do not know when such reclassification would become effective, how any transition rules would be formulated or applied, and whether or not the legal framework provided by the Hatch-Waxman Act would be preserved for some time after such reclassification.
As part of our microbubble franchise strategy, (i) we have developed and received FDA approval for DEFINITY RT, a modified formulation of DEFINITY, (ii) we look for other opportunities to expand our microbubble franchise, including new applications beyond echocardiography and ultrasound enhancing agent imaging generally such as our strategic arrangements with Cerevast, CarThera and Insightec, and (iii) we have completed construction of our specialized in-house manufacturing capabilities at our North Billerica facility for DEFINITY and, potentially, other sterile vial products. However, we can give no assurance that our microbubble franchise strategy will be successful or that a modified formulation, new patentsapplications or new manufacturing capabilities will protect the agent.grow our microbubble franchise.
40
Table of Contents
We have on-going development and technology transfer activities for a next generationbelieve DEFINITY product with SBL locatedRT will become commercially available in Songdo, South Korea, approximately 20 miles southwestthe fourth quarter of Seoul, but can give no assurances as to when those technology transfer activities will2021, although that timing cannot be completed and when we will begin to receive a supply of a next generation DEFINITY product from SBL. In addition, those activities could be adversely affected by on-going political and military tensions on the Korean peninsula.assured.
If we are not able to continue to (i) grow DEFINITY and DEFINITY RT sales, through increasedwhich depend on one or more of the growth of echocardiograms, the growth in the appropriate use of ultrasound enhancing agents in suboptimal echocardiograms, and our ability to sustain and grow our leading position in the U.S. echocardiography ultrasound enhancing agent market, penetration,or (ii) be successful with our microbubble franchise strategy, we willmay not be able to continue to grow the revenue and cash flow of the business or leverage the substantial overhead of the balance of our business, which could have a negative effect on our prospects.business, results of operations and financial condition.
Our dependence upon third parties for the manufacture and supply of a substantial portion of our products could prevent us from delivering our products to our customers in the required quantities, within the required timeframes, or at all, which could result in order cancellations and decreased revenues.
We obtain a substantial portion of our products from third party manufacturers and suppliers. We rely on JHS as our sole source manufacturer of DEFINITY, NEUROLITE, Cardiolite and evacuation vials. We rely on SBL as our sole source manufacturer of DEFINITY RT.
Based on our current estimates, we believe that we will have sufficient supply of DEFINITY, NEUROLITE, Cardiolite and evacuation vials from JHS, and sufficient supply of saline from our sole manufacturer, to meet expected demand. However, we can give no assurances that JHS or our other manufacturing partner will be able to manufacture and distribute our products in a high quality and timely manner and in sufficient quantities to allow us to avoid product stock-outs and shortfalls. In addition, on July 27, 2021, we received a letter from JHS that it was providing notice of non-renewal of our manufacturing agreement relating to DEFINITY, but that JHS remained interested in negotiating a new agreement. We are actively negotiating a new manufacturing agreement with JHS for DEFINITY, although there is no assurance that we will be able to reach an agreement on mutually acceptable terms or at all. In the event we are not able to enter into an agreement on mutually acceptable terms or at all, we expect that we would exercise our right under our current agreement with JHS to request a terminal supply of DEFINITY in an amount sufficient to meet our supply needs for DEFINITY until our in-house manufacturing facility is operational and producing enough DEFINITY to meet our supply needs, although there is no assurance that there would be no disruption.
Xenon is captured as a by-product of the Mo-99 production process. We receive bulk unprocessed Xenon from IRE resulting from highly-enriched uranium (“HEU”) Mo-99 production, which we process and finish for our customers. We do not yet receive Xenon resulting from low-enriched uranium (“LEU”) Mo-99 production at IRE and can give no assurances as to the timing of the availability of LEU Xenon. We believe we will have a sufficient supply of Xenon to meet our customers’ needs. However, until IRE converts to LEU Xenon production or we can qualify an additional source of bulk unprocessed Xenon, we will rely on IRE as a sole source provider of HEU Xenon.
1095 is currently manufactured only at the Center for Probe Development and Commercialization (“CPDC”). Until December 2019, the CPDC was subject to an Import Alert by the FDA, which restricted the CPDC’s ability to ship products to the U.S. Although the CPDC has since been cleared by the FDA to ship products to the U.S., there can be no guarantee that the CPDC, or any other third-party manufacturer that we may partner with in the future, will not be subject to similar restrictions in the future.
In addition to the products described above, for reasons of quality assurance or cost-effectiveness, we purchase certain components and raw materials from sole suppliers (including, for example, the lead casing for our TechneLite generators and the lipid blend material used in the processing of DEFINITY). Because we do not control the actual production of many of the products we sell and many of the raw materials and components that make up the products we sell, we may be subject to delays caused by interruption in production based on events and conditions outside of our control. At our North Billerica, Massachusetts facility, we manufacture TechneLite on a highly automated production line, as well as Thallium and Gallium using our older cyclotron technology and Xenon using our hot cell infrastructure. As with all manufacturing facilities, equipment and infrastructure age and become subject to increasing maintenance and repair. If we or one of our manufacturing partners experiences an event, including a labor dispute, natural disaster, fire, power outage, machinery breakdown, security problem, failure to meet regulatory requirements, product quality issue, technology transfer issue or other issue, we may be unable to manufacture the relevant products at previous levels or on the forecasted schedule, if at all. Due to the stringent regulations and requirements of the governing regulatory authorities regarding the manufacture of our products, we may not be able to quickly restart manufacturing at a third party or our own facility or establish additional or replacement sources for certain products, components or materials.
In addition to our existing manufacturing relationships, we are also pursuing new manufacturing relationships to establish and secure additional or alternative suppliers for our commercial products. We have also completed construction of our specialized in-house manufacturing capabilities at our North Billerica, Massachusetts facility. This project should not only deliver efficiencies and supply chain redundancy for our current portfolio but also should afford us increased flexibility as we consider external opportunities. However, we cannot assure you that these activities or any of our additional supply activities will be successful or that we will be able to avoid or mitigate interim supply shortages before new sources of product are fully functional and qualified. In addition, we cannot assure you that our existing manufacturers or suppliers or any new manufacturers or suppliers can
41
Table of Contents
adequately maintain either their financial health, technical capabilities or regulatory compliance to allow continued production and supply. A reduction or interruption in manufacturing, or an inability to secure alternative sources of raw materials or components, could eventually have a material adverse effect on our business, results of operations, financial condition and cash flows.
Our business and industry are subject to complex and costly regulations. If government regulations are interpreted or enforced in a manner adverse to us or our business, we may be subject to enforcement actions, penalties, exclusion and other material limitations on our operations.
Both before and after the approval of our products and agents in development, we, our products, development agents, operations, facilities, suppliers, distributors, contract manufacturers, contract research organizations and contract testing laboratories are subject to extensive and, in certain circumstances, expanding regulation by federal, state and local government agencies in the U.S. as well as non-U.S. and transnational laws and regulations, with regulations differing from country to country, including, among other things, anti-trust and competition laws and regulations and the recently enacted General Data Protection Regulation in the European Union. In the U.S., the FDA regulates, among other things, the pre-clinical testing, clinical trials, manufacturing, safety, efficacy, potency, labeling, storage, record keeping, quality systems, advertising, promotion, sale, distribution, and import and export of drug products. We are required to register our business for permits and/or licenses with, and comply with the stringent requirements of the FDA, the U.S. Nuclear Regulatory Commission, the U.S. Department of Health and Human Services, Health Canada, the European Medicines Agency, the U.K. Medicines and Healthcare Products Regulatory Agency, the NMPA, state and provincial boards of pharmacy, state and provincial health departments and other federal, state and provincial agencies. Violation of any of these regulatory schemes, individually or collectively, could disrupt our business and have a material adverse effect on our business, results of operations, financial condition and cash flows.
Under U.S. law, for example, we are required to report certain adverse events and production problems, if any, to the FDA. We also have similar adverse event and production reporting obligations outside of the U.S., including to the EMA and MHRA. Additionally, we must comply with requirements concerning advertising and promotion for our products, including the prohibition on the promotion of our products for indications that have not been approved by the FDA or a so-called “off-label use” or promotion that is inconsistent with the approved labeling. If the FDA determines that our promotional materials constitute unlawful promotion, it could request that we modify our promotional materials or subject us to regulatory or enforcement actions. Also, quality control and manufacturing procedures at our own facility and at third party suppliers must conform to cGMP regulations and other applicable law after approval, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMPs and other applicable law, and, from time to time, makes those cGMPs more stringent. Accordingly, we and others with whom we work must expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control. If in the future issues arise at a third party manufacturer, the FDA could take regulatory action which could limit or suspend the ability of that third party to manufacture our products or have any additional products approved at the relevant facility for manufacture until the issues are resolved and remediated. Such a limitation or suspension could have a material adverse effect on our business, results of operations, financial condition and cash flows.
We are also subject to laws and regulations that govern financial and other arrangements between pharmaceutical manufacturers and healthcare providers, including federal and state anti-kickback statutes, federal and state false claims laws and regulations, federal and state “sunshine” laws and regulations and other fraud and abuse laws and regulations.
We must offer discounted pricing or rebates on purchases of pharmaceutical products under various federal and state healthcare programs, such as the Medicaid drug rebate program, the “federal ceiling price” drug pricing program, the 340B drug pricing program and the Medicare Part D Program. We must also report specific prices to government agencies under healthcare programs, such as the Medicaid drug rebate program and Medicare Part B. As a specific example, in 2010, we entered into a Medicaid Drug Rebate Agreement with the federal government for some but not all of our products, and in 2016 entered into a separate Medicaid Drug Rebate Agreement for the balance of our products. These agreements require us to report certain price information to the federal government. Determination of the rebate amount that we pay to state Medicaid programs for our products, of prices charged to government and certain private payors for our products, or of amounts paid for our products under government healthcare programs, depends upon information reported by us to the government. If we provide customers or government officials with inaccurate information about the products’ pricing or eligibility for coverage, or the products fail to satisfy coverage requirements, we could be terminated from the rebate program, be excluded from participation in government healthcare programs, or be subject to potential liability under the False Claims Act or other laws and regulations.
Failure to comply with other requirements and restrictions placed upon us or our third party manufacturers or suppliers by laws and regulations can result in fines, civil and criminal penalties, exclusion from federal healthcare programs and debarment. Possible consequences of those actions could include:
• Substantial modifications to our business practices and operations;
• Significantly reduced demand for our products (if products become ineligible for reimbursement under federal and state healthcare programs);
42
Table of Contents
• A total or partial shutdown of production in one or more of the facilities where our products are produced while the alleged violation is being remediated;
• Delays in or the inability to obtain future pre-market clearances or approvals; and
• Withdrawals or suspensions of our current products from the market.
Regulations are subject to change as a result of legislative, administrative or judicial action, which may also increase our costs or reduce sales or otherwise adversely impact our products. For example, on April 16, 2021 in the case Genus Medical Technologies LLC v. Food and Drug Administration, the U.S. Court of Appeals for the D.C. Circuit held that a product (other than a combination product) that meets the definitions of both “drug” and “device” in the Federal Food, Drug, and Cosmetic Act (the “FDCA”) must be regulated as a device. On August 9, 2021, the FDA announced that, as part of its implementation of this court decision, the FDA intends to regulate products that meet both the device and drug definition as devices, except where Congress intended a different classification. The FDA further indicated that it intends to bring previously classified products into line with the court decision and will reexamine whether individual imaging agents meet the device definition. In connection with its announcement, the FDA requested comments from the industry on five topics: categories of products implicated by the court decision; the transition process; the transition timing; user fee transitions; and determining drug or device status. We plan to submit comments to the FDA in response to its request for comments by the November 30, 2021 deadline. While we question whether the FDA has authority to make this change, believe that pre-existing law already establishes that a broad spectrum of imaging agents have already been established by Congress to be “drugs”, and do not believe that any of our imaging agents meets the definition of a “device” under the FDCA, we can give no assurance that the FDA will agree with our position. In addition, if the FDA determines that one or more of our imaging agents meet the definition of a “device”, we do not know when such reclassification would be effective, how any transition rules would be formulated or applied, and whether or not the legal framework provided by the Hatch-Waxman Act would be preserved for some time after such reclassification. A reclassification of one or more of our imaging agents as a “device” could have a material adverse effect on our business, results of operations, financial condition and cash flows.
Ultrasound enhancing agents may cause side effects which could limit our ability to sell DEFINITY.
DEFINITY is an ultrasound enhancing agent based on perflutren lipid microspheres. In 2007, the FDA received reports of deaths and serious cardiopulmonary reactions following the administration of ultrasound micro-bubble enhancing agents used in echocardiography. Four of the 11 reported deaths were caused by cardiac arrest occurring either during or within 30 minutes following the administration of the ultrasound enhancing agent; most of the serious but non-fatal reactions also occurred in this time frame. As a result, in October 2007, the FDA requested that we and GE Healthcare, which distributes Optison, a competitor to DEFINITY, add a boxed warning to these products emphasizing the risk for serious cardiopulmonary reactions and that the use of these products was contraindicated in certain patients. In a strong reaction by the cardiology community to the FDA’s new position, a letter was sent to the FDA, signed by 161 doctors, stating that the benefit of these ultrasound enhancing agents outweighed the risks and urging that the boxed warning be removed. In May 2008, the FDA substantially modified the boxed warning. On May 2, 2011, the FDA held an advisory committee meeting to consider the status of ultrasound micro-bubble contrast agents and the boxed warning. In October 2011, we received FDA approval of further modifications to the DEFINITY label, including: further relaxing the boxed warning; eliminating the sentence in the Indication and Use section “The safety and efficacy of DEFINITY with exercise stress or pharmacologic stress testing have not been established” (previously added in October 2007 in connection with the imposition of the box warning); and including summary data from the post-approval CaRES (Contrast echocardiography Registry for Safety Surveillance) safety registry and the post-approval pulmonary hypertension study. Further, in January 2017, the FDA approved an additional modification to the DEFINITY label, removing the contraindication statement related to use in patients with a known or suspected cardiac shunt. Bracco’s ultrasound enhancing agent, Lumason, has substantially similar safety labeling as DEFINITY and Optison. In April 2021, after reviewing certain adverse events that occurred in patients with a prior history of allergic reactions to polyethylene glycol (“PEG”), an inactive excipient in both DEFINITY and Lumason, the FDA and the marketing authorization holders of these products agreed to an additional contraindication for use of these products, including advising clinicians to assess patients for prior PEG hypersensitivity before administering these products. If additional safety issues arise (not only with DEFINITY but also potentially with Optison and Lumason), this may result in unfavorable changes in labeling or result in restrictions on the approval of our product, including removal of the product from the market. Lingering safety concerns about DEFINITY among some healthcare providers or future unanticipated side effects or safety concerns associated with DEFINITY could limit expanded use of DEFINITY and have a material adverse effect on the unit sales of this product and our financial condition and results of operations.
In the U.S., we are heavily dependent on a few large customers and group purchasing organization arrangements to generate a majority of our revenues for our nuclear medical imaging products and our other products. Outside of the U.S., we rely primarily on distributors to generate a substantial portion of our revenue.
43
Table of Contents
In the U.S., we have historically relied on a limited number of radiopharmacy customers, primarily Cardinal, RLS, UPPI, GE HealthcareJubilant Radiopharma and Triad,PharmaLogic, to distribute our current largest volume nuclear imaging products and generate a majority of our revenues. Three customers accounted for approximately 30% of our revenues in the year ended December 31, 2016, with UPPI, Cardinal, and GE Healthcare accounting for approximately 11%, 10% and 9%, respectively.products. Among the existing radiopharmacies in the U.S., continued consolidations, divestitures and reorganizations may have a negative effect on our business, results of operations, financial condition orand cash flows. We generally have distribution arrangements with our major radiopharmacy customers pursuant to multi-year contracts, each of which is subject to renewal. Recently, we extended our contract with Jubilant Radiopharma with respect to certain products, other than TechneLite and Thallium-201, through December 31, 2023. If these contracts are terminated prior to the expiration of their term, or are not renewed, or are renewed on terms that are less favorable to us, then such an event could have a material adverse effect on our business, results of operations, financial condition and cash flows.
In Puerto Rico, we own and operate one of two radiopharmacies on the island and sell our own products as well as products of third parties to end users. In September 2017, Hurricane Maria devastated the island, interrupting power and telecommunications services for most of the island and limiting ground and air transportation. The building that houses our radiopharmacy sustained

minimal external physical damage as a result of the hurricane. From and after September 20, 2017, the number of diagnostic imaging procedures performed on the island has severely declined. While we currently believe that the number of diagnostic imaging procedures performed in Puerto Rico will slowly return to prior levels, we can give no assurances of that, and failure of our radiopharmacy to return to such prior levels could have a negative effect on the revenue and cash flow of our business.
For all of our medical imaging products, we continue to experience significant pricing pressures from our competitors, large customers and group purchasing organizations, and any significant, additional pricing pressures could lead to a reduction in revenue which could have a material adverse effect on our business, results of operations, financial condition and cash flows.
Outside of the U.S., and Canada, and Puerto Rico, we have no sales force and, consequently, rely on third-party distributors, either on a country-by-country basis or on a multi-country, regional basis, to market, sell and distribute our products. This is the case in bothIn Canada, and Australia, where we formerly owned or operated radiopharmacies and are now distributing products under the Isologic Agreement and the GMS Agreement, respectively. Distributors accounted for approximately 34%, 15% and 17% of International segment revenues for the years ended December 31, 2016, 2015 and 2014, respectively.maintain our own direct sales force to sell DEFINITY. In certain circumstances, distributors may also sell competing products to our own or products for competing diagnostic modalities and may have incentives to shift sales towards those competing products. As a result, we cannot assure you thatthat our international distributors will increase or maintain current levels of unit sales or that we will be able to increase or maintain our current unit pricing, which, in turn, could have a material adverse effect on our business, results of operations, financial condition and cash flows.
Our business is subject to international economic, politicalThe CVRs we issued as part of the Progenics Acquisition may result in substantial future payments and other risks that could negatively affect our results of operations or financial position.
Fordivert the years ended December 31, 2016, 2015 and 2014, we derived approximately 15%, 20% and 22%attention of our revenues from outsidemanagement; in addition, the fifty United States, respectively. Accordingly,actual payments made in connection with the CVRs, if any, may not be consistent with the estimated fair value of the CVRs that we are required to prepare for accounting purposes.
As part of the consideration for the Progenics Acquisition, we issued CVRs to the stockholders of Progenics and holders of in-the-money Progenics equity awards entitling them to future cash payments of 40% of PYLARIFY net sales over $100.0 million in 2022 and over $150.0 million in 2023. These payments could be substantial and could adversely impact our business is subjectliquidity. In addition, we are obligated to risks associatedexercise a level of effort, expertise and resources consistent with doing business internationally, including:
Less stable political and economic environments and changesthose normally used in a specific country’s or region’s political or economic conditions, including on-going politicalmedical diagnostics business similar to our size and military tensions on the Korean peninsula which could adversely affect our next generation DEFINITY program at SBL;
Entering into or renewing commercial agreements with international governments or provincial authorities or entities directly or indirectly controlled by such governments or authorities, such as our Chinese partner Double-Crane Pharmaceutical Company;
International customers which are agencies or institutions of foreign governments;
Local business practices which may be in conflict with the U.S. Foreign Corrupt Practices Act and U.K. Bribery Act;
Currency fluctuations;
Potential negative consequences from changes in tax laws affecting our ability to repatriate profits;
Unfavorable labor regulations;
Greater difficulties in relying on non-U.S. courts to enforce either local or U.S. laws, particularlyresources with respect to intellectual property;developing, seeking regulatory approval for and commercializing a product of similar market potential at a similar stage in its development or product life to PYLARIFY. We are also required to produce net sales statements for PYLARIFY that may be reviewed and challenged by CVR holders, with any disagreement to be resolved by an independent accountant. These requirements could divert management time and resources and result in additional costs.
Greater potentialBecause the CVRs are considered contingent consideration liabilities, for intellectual property piracy;
Greater difficultiesaccounting purposes we are required by U.S. GAAP to estimate their fair value on a recurring basis. Adjustments in managingthe estimated fair value of the CVRs can impact our consolidated financial statements on a quarterly or annual basis. The estimated fair value of the CVRs is determined based on a Monte Carlo simulation model that include significant estimates and staffing non-U.S. operations;
The needassumptions pertaining to ensure compliancecommercialization events, sales targets, market conditions and discount rates. These estimates and assumptions are subject to the judgment of our management team and are not prepared with the numerous in-country and international regulatory and legal requirements applicablea view towards public disclosure of projected sales. Our sales targets are also subject to our business in each of these jurisdictions and to maintain an effective compliance program to ensure compliance with these requirements;
Changes in public attitudes about the perceived safety of nuclear facilities;
Changes in trade policies, regulatory requirementssignificant economic, competitive, industry and other barriers;
Civil unrest or other catastrophic events, including Hurricane Mariauncertainties and contingencies, which are difficult to predict and in Puerto Rico; and
Longer payment cycles of non-U.S. customers and difficulty collecting receivables in non-U.S. jurisdictions.
These factorsmany cases are beyond our control. The realizationWe can give no assurance that the actual amounts paid, if any, in connection with the CVRs will be consistent with any recurring fair value estimate for such CVRs.

44
Table of any of these or other risks associated with operating outside the fifty United States could have a material adverse effect on our business, results of operations, financial condition and cash flows. As our international exposure increases and as we execute our strategy of international expansion, these risks may intensify.Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Repurchases
The following table presents information with respect to purchases of common stock we made during the quarter endingthree months ended September 30, 2017.2021. The Company does not currently have a share repurchase program in effect. The 2015 Equity Incentive Plan, adopted by the Company on June 24, 2015, andas amended on April 26, 2016 and as further amended on April 27, 2017, April 24, 2019 and April 28, 2021 (the “2015 Plan”), provides for the withholding of shares held by employees to satisfy minimum statutory tax withholding obligations. It does not specify a maximum number of shares that can be withheld for this purpose. The shares of common stock withheld to satisfy minimum tax withholding obligations may be deemed to be “issuer purchases” of shares that are required to be disclosed pursuant to this Item.Item 2. These shares are then sold in compliance with Rule 10b5-1 into the market to allow the Company to satisfy the tax withholding requirements in cash.
PeriodTotal Number of 
Shares Purchased		Average Price Paid 
per Share		Total Number of 
Shares Purchased as
Part of Publicly
Announced Programs		Approximate Dollar
Value of Shares that 
May Yet Be Purchased Under
the Program
July 2021**1,086 $26.20 **
August 2021**1,077 $25.63 **
September 2021**2,737 $25.61 **
Total4,900 *
Period 
Total Number of 
Shares Purchased
 
Average Price Paid 
per Share
 
Total Number of 
Shares Purchased as
Part of Publicly
Announced Programs
 
Approximate Dollar
Value of Shares that 
May Yet Be Purchased Under
the Program
July 2017** —
 $—
 * *
August 2017** 27,918
 $17.48
 * *
September 2017** 37,860
 $16.80
 * *
Total 65,778
   *  
    ________________________________
*     These amounts are not applicable as the Company does not have a share repurchase program in effect.
**    Reflects shares withheld to satisfy minimum statutory tax withholding amounts due from employees related to the receipt of stock which resulted from the exercise or vesting of equity awards.
restricted shares from equity-based awards.
Dividend Policy
We did not declare or pay any dividends, and we do not currently intend to pay dividends in the foreseeable future. We currently expect to retain future earnings, if any, for the foreseeable future, to repay indebtedness and to finance the growth and development of our business.business and to repay indebtedness. Our ability to pay dividends areis restricted by our financing arrangements. See Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources-External Sources of Liquidity” for further information.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
On October 30, 2017,July 27, 2021, we entered intoreceived a binding commercial supply arrangement pursuantletter from JHS that it was providing notice of non-renewal of our manufacturing agreement relating to whichDEFINITY, but that JHS remained interested in negotiating a new agreement. We are actively negotiating a new manufacturing agreement with JHS for DEFINITY, although there is no assurance that we will be able to reach an agreement on mutually acceptable terms or at all. In the event we are not able to enter into an agreement on mutually acceptable terms or at all, we expect that we would exercise our right under our current agreement with JHS to request a terminal supply Cardinal Health with TechneLite generators, Xenon, Neuroliteof DEFINITY in an amount sufficient to meet our supply needs for DEFINITY until our in-house manufacturing facility is operational and other products through 2018.  Theproducing enough DEFINITY to meet our supply arrangement specifies pricing levels and requires Cardinal Health to purchase minimum volumesneeds, although there can be no assurance that there would be no disruption.
45
Table of certain products from us during certain periods.  The supply arrangement will expire on December 31, 2018 and may be terminated upon the occurrence of specified events, including a material breach by the other party and certain force majeure events.Contents

Item 6. Exhibits
INCORPORATED BY REFERENCE
EXHIBIT

NUMBER
DESCRIPTION OF EXHIBITSFORM
FILE

NUMBER
EXHIBIT
FILING

DATE
31.1*
31.2*
31.2*
32.1**
32.1*
101.INS*
101.INS*Inline XBRL Instance Document
101.SCH*
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*Cover Page Interactive Data File (embedded within the Inline XBRL document)
*Filed herewith

*    Filed herewith.
**    Furnished herewith.



46
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
LANTHEUS HOLDINGS, INC.
By:/s/ MARY ANNE HEINO
Name:Mary Anne Heino
Title:
President and Chief Executive Officer
(Principal Executive Officer)
Date:November 2, 20174, 2021
LANTHEUS HOLDINGS, INC.
By:/s/ JOHN W. CROWLEYROBERT J. MARSHALL, JR.
Name:John W. CrowleyRobert J. Marshall, Jr.
Title:Chief Financial Officer and Treasurer (Principal
(Principal Financial Officer and Principal Accounting Officer)
Date:November 2, 20174, 2021



34
47